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INTRODUCTION 
Diabetes Mellitus 
Diabetes mellitus is a disorder characterized by the metabolic 
consequences of deficient insulin action. There are two major types 
of the disorder (l), type I (insulin dependent diabetes mellitus) and 
type II (insulin independent diabetes mellitus). The impairment of 
glucose metabolism results in high blood glucose (hyperglycemia) and in 
high amounts of glucose in the urine (glycosuria). In addition, there 
is a decrease in glycolysis, lipogenesis, and glycogen synthesis as 
well as an increase in gluconeogenesis from amino acids, an increase 
in the breakdown of glycogen and lipids, and an increase in ketogenesis 
from fatty acids. The demand for energy is met to a greater degree 
by lipid and protein metabolism. 
Recent studies have shown that while a predisposition to diabetes 
may be linked to the D-Dr locus of the HLA gene (human leukocyte anti­
gen) , insulin dependent diabetes mellitus is not a simple consequence 
of genetic make up (2). In many cases some type of environmental 
stress appears to play a role, such as viruses, drugs, or other unknown 
factors (2) . In fact, all viruses found to produce diabetes in exper­
imental animals have been shown to infect the g-cell of the pancreas 
but not the CT-cell (3). 
The absence of insulin leads to tissue wasting and ultimately 
to death. The key target tissues appear to be the liver, muscle, and 
adipose tissue, although insulin does influence the metabolism and 
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function of most tissues. One of the major functions of insulin is to 
coordinate the relative rates of fuel uptake, storage, and mobilization 
with the varying needs of the organism and with the varying availa­
bility of fuel from the diet. One of the earliest detectable actions 
of insulin on muscle is a rapid stimulation of the transport of glucose 
and amino acids (1). This happens within seconds to minutes. Within 
the time frame of minutes to hours, the effects of insulin on muscle 
include (2) those on carbohydrate metabolism; increased glycogen syn­
thesis, increased glycolysis, and decreased gluconeogenesis. Also seen 
are increases in protein synthesis and decreases in protein degrada­
tion. Long term effect (hours to days) include an increase in RNA and 
DMA synthesis (2). 
Insulin serves to connect the protein reserves in the muscle with 
the energy status of the rest of the organism. With low insulin levels, 
proteolysis in muscle provides gluconeogenic substrates to fuel those 
tissues which ultimately rely on glucose. Insulin acts on carbohydrate 
metabolism to ensure that glucose is rapidly removed from the blood and 
utilized when the blood glucose concentration is above fasting levels. 
This serves to keep the period of hyperglycemia, which follows the in­
take of carbohydrates, to a minimum. The uptake of glucose into muscle 
is increased by insulin, as is the activity of glycogen synthase. At 
this same time, phosphorylase activity is decreased and so glycogen 
synthesis is favored. When the glycogen stores are full, the excess 
glucose is oxidized to CO^ via glycolysis and Krebs cycle. It is 
not surprising then that insulin does affect many enzymes of glycolysis 
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and the Krebs cycle. The mechanism(s) by which insulin exerts its 
action is not at all clear at this time. There are many excellent 
reviews concerning these theories of insulin action (4,5,6). Theories 
range from peptide second mediators to changes in the intracellular 
+2 
Ca concentration to changes in the phosphorylation states and combi­
nations of these. No matter what the second messenger(s) is, it is 
clear that insulins' influence on the skeletal muscle is very impor­
tant and in turn that the muscle plays a vital role in the overall 
metabolic status. 
Hexokinase 
Meyerhof (7) was the first to use the term hexokinase to describe 
a preparation from yeast which catalyzed the phosphorylation of glucose 
by ATP. Soon thereafter, hexokinase activity was found in mammalian 
tissues (8). It has been known since the early 1960s that two hexo­
kinase activities exist in the liver (9-13). One activity has a low 
for glucose and the other activity has a high for glucose (re­
ferred to as glucokinase). Several laboratories (9,10,12-14) re­
ported that the high K glucokinase was subject to nutritional and 
hormonal control. Glucokinase was reported to decrease upon starvation 
or diabetes and to increase with refeeding or the administration of 
insulin (9,10,12-14). No evidence was presented at that time for the 
same control of the low activity. 
At that time, hexokinase was regarded as a single enzyme in 
tissues other than liver. Hexokinase activities were designated by 
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the tissue of their origin, i.e., adipose tissue hexokinase, skeletal 
muscle hexokinase, brain hexokinase and so on. 
In 1954, Gonzalez et al. (15) utilized ion-exchange column 
chromatography to demonstrate the existence of four separate hexokinase 
activities in liver, one high actvity (glucokinase) and three low 
activities. Shortly afterward, Katzen et al. (16) demonstrated the 
presence of these same four activities in rat liver and human cell cul­
ture lines using a starch gel electrophoretic assay. This assay employs 
an activity stain to visualize the different hexokinase activity bands 
on the gel. The differing types of hexokinase found were designated 
by Katzen (17) as I, II, III, and IV in order of increasing mobility 
toward the anode in the electrophoretic assay system. Type IV is the 
high glucokinase from liver. Katzens' laboratory also reported (15) 
that the approximate values for glucose for the different enzyme 
forms were different. These approximate K^s were determined on the 
basis of staining intensities at varying concentrations of glucose. 
The K^s, in terms of order of magnitude, were reported to be (16,18) 
10 for type I, 10 for type II, 10 for type III, and 10 for 
type IV. Type IV was later identified as glucokinase on the basis of 
kinetic studies and its disappearance in the fasted and diabetic state. 
In addition to the liver and human cell culture lines, the three 
low K hexokinases were found in various tissues in the rat and the 
m 
relative amounts of each hexokinase type in different tissues was found 
to differ (l8-20). Similar distributions of the hexokinases were found 
in a variety of mammals, including the rat, hamster, monkey, rabbit. 
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and cow (l9,21,22). Figure 1 (17) illustrates these relative amounts 
of the hexokinases in various tissues of the rat. 
The question concerning the true isozymic nature of these hexo­
kinases, that is if they actually represented different proteins, was 
quickly addressed. Grossbard and Schimke (20,22) and Katzen (l7 ) 
showed that these three types of hexokinase, when partially purified 
from different tissues, retained the same characteristics as measured 
by DEAE-chromatography, gel electrophoresis, for glucose, and sen­
sitivity to trypsin or heat. They reported that these characteristics 
were the same for crude extracts and the partially purified enzyme 
regardless of the tissue source. The fact that the three types retain 
their unique electrophoretic and chromatographic properties even 
after multiple purification steps (22) indicates that the three types 
are not an artifact of preparation. 
The three low hexokinases can be distinguished by their sen­
sitivity to inactivation (20,22). While type I hexokinase is very 
stable towards inactivation at 45°G, the type III is moderately stable, 
but type II is very instable (i6,20,22). This same relative pattern is 
seen with inactivation of the hexokinases by the action of proteases 
(22), guanidine-HCL, N-ethyl maleimide, and with pH extremes (22). In 
a more complete study on the sensitivity to heat and tryptic inactiva­
tion, Grossbard and Schimke (20) demonstrated that these relative sen­
sitivities held for the hexokinases regardless of the tissue origin. 
Kaji et al. (23) showed that multiple forms of yeast hexokinase 
were a result of proteolysis. While proteolytic attack on the mammalian 
Figure 1. Summary of tissue distribution of hexokinase types I, II, 
and III in the rat. Relative activities of hexokinase 
were determined by Katzen (22) utilizing the starch gel 
electrophoretic technique. Relative activity levels are 
), intermediate ( ), designated as high ( -T—n 
low ( ), and questionable ( I | ) 
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hexokinases does produce fragments with differing mobilities on starch 
gels, no interconversion of the three types has been observed as a re­
sult of proteolysis (17). Hexokinase I does produce a second form, 
seen on starch gel electrophoresis, which migrates slightly quicker 
than the native form. Hexokinase III shows no difference in migratory 
properties, while proteolysis of hexokinase II produces three bands, 
none of which migrate close to the native forms of hexokinase I, II, 
or III or close to the proteolytic bands from hexokinase I (22). So, 
it is clear that these hexokinases do not represent native proteolytic 
forms of one protein. In support of this contention, it was found that 
upon prolonged incubation of the crude extract or tissue, no alterations 
in the electrophoretic profiles were seen (18). This also eliminated 
the possibility that these hexokinase types represented different di­
gestion products formed during purification. 
Further studies dealing with the question of the true isozymic 
nature of these three low K hexokinases have utilized immunological 
m 
techniques. Numerous studies have demonstrated a lack of immunological 
cross reactivity between the three low K hexokinases themselves and 
m 
with glucokinase as well (24-28). Pilkis et al. (24) saw no cross 
reactivity with the low hexokinases when testing an antibody raised 
against glucokinase. In 1972, Creighton et al. (28) demonstrated that 
antibody raised against partially purified hexokinase II from rat did 
not cross react with hexokinase I, glucokinase, or yeast hexokinase. 
This demonstrated that hexokinase II was different from these enzymes. 
In 197%, Neumann and Pfleiderer (29) and Neumann et al. (30) demon­
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strated that antibody raised against hexokinase I or hexokinase III did 
not react with hexokinase II. This was tested by inhibition of enzyme 
activity by antibody, immunoprecipitation, and electroimniunodiffusion 
techniques. These results were confirmed in 1975 by Ouchi and Ishibashi 
(25). 
In 1975, Povey and his colleagues (31) reported that hexokinase 
III was the product of a gene locus which was independent of hexokinase 
I and further (32) that hexokinase I and hexokinase II were also deter­
mined by separate genes. Ureta (33) confirmed this in 1982, He re­
ported that the hexokinases were products of independent genes rather 
than hybrid molecules. 
Despite the afore mentioned studies, conflicting reports dealing 
with cross reactivity between the hexokinases have come from the labor­
atory of Lawrence, Walker, and Trayer (34). They reported that while 
antibody raised against hexokinase I does not react with hexokinase II, 
some preparations of antibody raised against hexokinase II did react 
with hexokinase I while other preparations did not. This is most likely 
due to impure preparations of the antigen for hexokinase II. While 
hexokinase I is purified from brain, which most likely contains only 
hexokinase I, hexokinase II is purified from muscle which also contains 
hexokinase I. Their enzyme preparations were tested using gel electro­
phoresis, but only under denaturing conditions. Since both hexokinases 
are of the same molecular weight they would fail to detect contamination 
by hexokinase I. It is ver}' likely that the cross reactivity seen in 
their studies represents impure antigen and not homology between the 
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hexokinases. 
From studies on inactivation, kinetics, and immunological prop­
erties, it is clear then that the hexokinases do represent isozymes, 
i.e., distinct proteins. As mentioned earlier, the three hexokinases can 
be distinguished on the basis of different kinetic properties. Indeed 
the for glucose was one of the earliest properties employed to dif­
ferentiate these hexokinase activities (15). Even prior to the knowl­
edge that hexokinase existed in different forms within the same tissue, 
investigators had reported that the kinetic properties of hexokinase 
partially purified from different tissues were not the same. In 1962, 
Fromm and Zewe (35) reported that partially purified hexokinase from 
calf brain (hexokinase type I) showed a for glucose on the order of 
10 ^K. This was in agreement with the later approximations made utiliz­
ing the starch gel electrophoretic assay (16,20) for hexokinase I. The 
values obtained for hexokinase activity from muscle were between the 
values for pure hexokinase I and hexokinase II (36). This is be­
cause the hexokinase activity in this tissue consists of both hexokinases. 
Early studies by Grossbard and Schimke (20) pointed out that 
there were many similarities in the hexokinases types I, II, and III. 
Although these properties do differ slightly in degree, all three of 
these hexokinases demonstrate; 1) extreme sensitivity to inhibition by 
the product, glucose 6-phosphate, 2) moderate sensitivity to inhibition 
by ATP, 3) the same nucleotide specificity, with ATP resulting in the 
highest activity and IT? showing appreciable activity, 4) a broad pH 
optimum around 8.4, 5) a Vmax for fructose to Vmax for glucose ratio of 
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1-1.2, and 5) the same molecular weight of the range 95,000-100,000. 
It w^s reported in the early 1970s that the regulation of these hexo-
kinases was different. While hexokinase I, II, and III are inhibited 
by glucose 5-phosphate, this inhibition is relieved by orthophosphate 
for hexokinase I alone (37). The glucose 5-phosphate inhibition of 
hexokinase II, and hexokinase III is not relieved by orthophosphate 
( 3 8 , 3 9 ) .  
Early studies concerning the effects of the diabètic state on 
hexokinase activity has led to conflicting observations concerning 
the hormonal regulation of hexokinase activity. Before it was known 
that hexokinase existed in three isozymic forms, researchers demon­
strated that in alloxan-induced diabetes, glucose utilization in the 
heart and skeletal muscle was decreased (8,40,41). It was not clear 
if this was due to impaired glucose transport, impaired glucose phos­
phorylation, or both. Studies from other laboratories (42,43) pre­
sented evidence that these two processes were not necessarily coupled. 
Shortly following the reports of the existence of different 
forms of hexokinase came evidence that it was the hexokinase type II 
which responded to changes in nutritional and hormonal status (15,17, 
18). Katzen et al. (16) demonstrated that hexokinase II increased in 
cell cultures in response to high media glucose concentrations, and 
that the levels of hexokinase II were altered in some tissues with the 
age of the animal (18). 
Several laboratories presented evidence that the low hexokinase 
activity was not altered in the heart muscle (9,44) or in the liver 
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(9,10,45) of diabetic rats. However, reports from other laboratories 
did demonstrate a decrease in the hexokinase II activity in muscle, 
liver, and other insulin sensitive tissues in the diabetic rat (16,46-
53). These studies suggested that hexokinase II was under hormonal 
regulation in insulin sensitive tissues. Prior to extensive studies 
on the distribution profiles of hexokinase types in various tissues, 
the suggestion was made (16) that the more highly sensitive a tissue 
was to insulin, the higher the proportion of hexokinase II in that 
tissue. As shown in Figure 1 (17), skeletal muscle, heart muscle, and 
fat pad, which are all highly insulin sensitive, contain a large pro­
portion of hexokinase II. Hexokinase II is low in those tissues which 
are relatively insulin insensitive, such as kidney and brain. Earlier 
studies (15,18) had indicated that hexokinase I and hexokinase II were 
not subjected to nutritional and hormonal control. However, bzsed on more 
thorough distribution studies, Katzen (17) suggested that the overall 
action of insulin on carbohydrate metabolism involved all the hexokinase 
isozymes. A hypothesis was presented (17) which took into account the 
involvement of all the hexokinase isozymes in the total picture of the 
action of insulin. While the most insulin sensitive tissues do contain 
a large amount of hexokinase II (diaphragm, gastrocnemius, young fat 
pad, heart), the activity of hexokinase II is also high in some tissues 
that do not seem to require insulin (testes, adrenals, intestine, thymus, 
lung, spleen). The relative proportions of the hexokinase isozymes 
are illustrated in Figure 1. From this it appeared to Katzen (17), 
that it was actually the hexokinase I which was in the pivital role in 
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the determination of the insulin sensitivity of a tissue. If large 
amounts of hexokinase I are present, the tissue overcomes the require­
ment for insulin, or at least this requirement is diminished. Although 
Katzen concluded that it was not the presence of hexokinase II but a 
lowered hexokinase I content coupled with a deficiency in hexokinase II 
and III which corresponds to the tissue sensitivity, it is hexokinase 
II activity which decreases with the lack of insulin (5U). Experi­
mentation has a-lso determined that hexokinase II activity increases 
in response to treatment of the streptozotocin-diabetic rat with in­
sulin (54,55). 
Although Moore et al. (46) mistakenly identified hexokinase II 
as hexokinase type IV, they reported a decrease in this enzyme in the 
fat pad of fasting rats. Making the same misidentification, Gromova 
(48) and Gromova and Il'Yin (49) demonstrated that the hexokinase II 
activity in the fat pad of the alloxan-diabetic rat decreased. They 
demonstrated further that the activity increased upon the administra­
tion of insulin. These results were later confirmed by Hansen, Pilkis, 
and Krahl (50). Some of the confusion in identifying hexokinase II 
as hexokinase IV (glucokinase) may have arisen out of early studies 
by Stein, Cori, and Cori (56). In their studies, they suggested that 
the liver, and possibly the muscle and adipose tissues, contained a 
glucokinase, that is, an enzyme which was specific for glucose and would 
not use fructose as a substrate. Katzen et al. (21) and Katzen (17) 
demonstrated that the hexokinase II activity in rat skeletal muscle and 
fat pad decreased with starvation or streptozotocin-induced diabetes. 
and reappeared upon refeeding or the administration of insulin. They 
also reported no effect of starvation or diabetes on the activity of 
hexokinase I in the skeletal muscle and a possible slight increase in 
the activity of hexokinase III in the diabetic muscle (17). 
In 1966, McLean et al. (47) reported a decrease in hexokinase II 
activity in adipose tissue of the alloxan-diabetic rat. They employed 
a spectrophotometric assay as opposed to the gel electrophoretic assay 
or ion-exchange' chromatography followed by gel electrophoretic assay. 
Thus it appeared, by several methods of isozymic separation, gel electro­
phoretic assays (16,17,21,48,49), evaluation of peak activity following 
ion-exchange chromatography (57), spectrophotometric assays at differ­
ent glucose concentrations (47,50,58), and heat inactivation of hexo­
kinase II (18^58)^ that the diabetic state, and in turn insulin, in­
fluenced hexokinase II activity in some tissues of the rat. It was 
clear by the late 1960s that glucokinase was not the only hexokinase 
activity that was affected by the nutritional and hormonal status of 
the animal. In insulin sensitive tissues, studies (17) have shown that 
it is hexokinase II which decreases upon fasting or the induction of 
the diabetic state (16,17,18,54). 
There are many ways in which the action of insulin on hexokinase 
II activity could be mediated. Several of these have been discounted 
and all of the suggestions listed below will be discussed in further 
detail. The possible mechanisms include; a) by a coupling to glucose 
transport such that the concentration of glucose controls the rate of 
phosphorylation and hence the activity of hexokinase II, b) by an 
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association of hexokinase II with the plasma membrane, c) by an asso­
ciation of hexokinase II with the mitochondrial membrane, d) by a 
direct interaction of hexokinase II with the insulin molecule, e) by 
the interconversion between the different hexokinase types, f) by the 
inhibition of hexokinase II by product, glucose 6-phosphate, g) by 
the inhibition of hexokinase II activity by other effector molecules 
such as glucose 1,5-diphosphate, h) by the alteration of the rate of 
synthesis of hexokinase II, i) by an alteration in the rate of degra­
dation of the hexokinase II, and j) by the covalent modification of 
the hexokinase II to regulate the activity or the sensitivity to other 
effector molecules. 
It has been suggested (40,41) that glucose transport and phos­
phorylation might be coupled such that an increase in glucose transport 
would then increase the rate of phosphorylation of glucose and in this 
way insulin could regulate hexokinase II activity. It is now known 
that these two processes are not coupled (42,43) and that at high intra­
cellular glucose concentration the phosphorylation of glucose can be­
come the rate limiting step (59). Bessman (50) has reported that this 
"glucose permeability" theory does not account for all the effects ob­
served with insulin, and that the increase in transport is not neces­
sary to achieve the increase in hexokinase activity seen in response 
to insulin. 
Emmelot and Bos (51) reported a possible interaction between 
hexokinase and the inner surface of the plasma membrane. They suggested 
that the administration of insulin to diabetic rats might release 
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the hexokinase (inactive when bound) and the unbound hexokinase would 
then be active and so increase the cells' capacity for glucose phosphory­
lation, Other researchers (55) have suggested a mechanism which is the 
opposite, i.e., hexokinase would be more active if associated with the 
membrane. However, no evidence was found for an association of hexo­
kinase with the plasma membrane (55). This hypothesis was most likely 
suggested with the knowledge that hexokinase in the brain was bound to 
the particulate fraction (52,63). 
This information, coupled with differences in the time course 
of reactivation of hexokinase II activity in the heart and skeletal 
muscle upon the administration of insulin to diabetic rats (45) led 
Katzen to suggest that the sensitivity of hexokinase II to diabetes 
might be related to the cytosolic distribution of the hexokinase 
types in various tissues that are sensitive to insulin. 
In 1954, Bessman (54) proposed the hexokinase mitochondrial 
binding theory of insulin action. He suggested that insulin either 
dirctly or indirectly increases the coupling of hexokinase to the 
mitochondria. This creates a compartment and so increases the coupling 
efficiency between energy production (oxidative phosphorylation) and 
energy-requiring processes. Bessman and Geiger have written an excel­
lent review dealing with this hypothesis (65). In 1972, Bessman (60) 
reported an enhanced vitro binding of hexokinase II to mitochondria 
isolated from the leg muscle of normal rats receiving insulin prior to 
sacrifice. A reversible association of hexokinase II with isolated 
skeletal muscle mitochondria has been confirmed (55,67) and this hexo-
17 
kinase is solubilized by glucose 5-phosphate and ATP and the dissocia­
tion is retarded by divalent cations (Mg^~, Mn^^, and Ca^^) (58). The 
in vivo consequences are not yet clear. Whether changes in solubiliza­
tion are due to metabolite concentration changes vivo and whether 
this plays a role in the regulation of hexokinase II activity is not 
certain at this time. It has been suggested that, at least for hexo­
kinase I, the product, glucose 5-phosphate, might mediate the sol­
uble/bound distribution. Studies from two groups (55,69) have demon­
strated that this is probably not physiological for hexokinase I and 
II. 
It is not clear what role binding might play in affecting the 
kinetic properties of hexokinase II. There have been many reports of 
differences in kinetic properties between the bound and soluble enzyme 
(70-74). However there is no doubt that the bound and soluble enzymes 
do not represent additional forms of hexokinase, but are the same pro­
teins (70,72,73). Sprengers et al. (75) have reported a decreased 
affinity of hexokinase I for glucose 1,5-diphosphate when the enzyme 
is bound. Glucose 1,6-diphosphate is an inhibitor of the hexokinase 
activity (76). In another study (77), a decreased affinity of both 
bound hexokinase I and hexokinase II for glucose 1,6-diphosphate was 
reported with little difference found in the other kinetic parameters. 
It was also noted that in the particular tumor line used in the study , 
less hexokinase II was bound than soluble, but that most of the hexo­
kinase I was bound. Katzen and his colleagues (57) demonstrated that 
even in the normal rat the majority of hexokinase II in the gastro-
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cnemius is soluble. These same results were obtained by Berstein and 
Kipnis (58) who reported little hexokinase II bound in skeletal muscle 
while approximately 50% of the hexokinase II was bound in adipose tissue. 
It is evident then that the role that the binding of hexokinase II to 
the mitochondria plays in the regulation of the enzyme activity is not 
conclusive. 
Preliminary studies in Katzen's laboratory (17) indicated that 
the inclusion of a thiol in the extraction steps and the gel electro-
phoretic assay might mask the effect of the diabetic state on the hexo­
kinase II activity. Katzen (17) reported the appearance of two bands 
of hexokinase II activity in the starch gel electrophoretic assay. 
These two electrophoretically distinguishable bands were seen with 
2-mercaptoethanol omitted from the tissue extraction buffer and the 
electrophoretic buffers (17,54,55). No difference was found in the 
level of hexokinase II in the diabetic or the normal rat heart or fat 
pad when assayed in the presence of 2-mercaptoethanol, (17). In the 
absence of 2-mercaptoethanol only one band of the two electrophoreti­
cally distinguishable forms appeared to be affected by the diabetic 
state. In these same studies Katzen also observed that the addition 
of insulin directly to the diabetic tissue extracts from heart muscle 
increased the activity of hexokinase II. This same effect was seen 
upon the addition of glutathione (GSH) to the extracts. On the basis 
of their observations, and since insulin contains a number of disulfide 
bonds, the suggestion was made that perhaps insulin exerted its control 
by way of a thiol-disulfide interchange reaction between insulin and a 
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form of hexokinase II f17,54,55). Keep in mind that investigators did 
not realize at this time that insulin could be working through a recep­
tor and mediators. In 1959, Cuatrecasas (78) first demonstrated that 
insulin need not enter the cell to accelerate glucose transport into 
the adipocyte. At any rate, the suggestion of a direct interaction 
with insulin was dropped when other studies from a number of labora­
tories , including Katzens', reported that the effect of diabetes on 
hexokinase II in adipose was observable with 2-mercaptoethanol in the 
extraction buffers and with the measurement of hexokinase activity by 
spectrophotometric procedures (4-7,50,51,53,79). 
Another hypothesis suggested concerning the action of insulin on 
hexokinase II was that perhaps the differing hexokinase types were 
different dimeric combinations of two unlike polypeptide chains, 
Murakami and Ishibashi (80) suggested in 1972 that hexokinase II and 
hexokinase III may be interconvertable, perhaps by a thiol-disulfide 
exchange. They also suggested that the nutritional and hormonal status 
of the animal influenced this interconversion. However, in 1956, 
Grossbard and Schimke had shown (20) that the molecular weight of the 
hexokinase types I, II, and III were all between 96,000 and 99,000 in 
denaturing or nondenaturing conditions. So the possibility of dimeric 
combinations seemed very unlikely. Further support against the dimer 
hypothesis catne when Chou and Wilson (81) showed that glycine was the 
only detectable N-terminal amino acid in highly purified brain hexo­
kinase, and they also reported seeing only one band under denaturing 
conditions. On the basis of immunological cross reactivity studies. 
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Ouchi and Ishibashi (25) discounted their original hypothesis. 
The suggestion has also been presented that the decrease in hexo-
kinase II activity in the diabetic rat heart and skeletal muscle is 
due to increased levels of glucose 6-phosphate which results in the 
inhibition of enzyme activity ('+4,82). However reports show that in 
the streptozotocin-diabetic rat heart muscle there is a decrease in 
hexokinase II activity while there is no elevation of glucose 6-phosphate 
levels (83). In addition, in studies on hexokinase II levels which 
employed the gel electrophoretic assay, glucose 6-phosphate should have 
been separated from the hexokinase II during the electrophoresis. So 
even if some of the decrease in activity were due to inhibition of 
hexokinase II by glucose 6-phosphate, this certainly cannot account 
for the decrease in activity in the absence of glucose 6-phosphate (54). 
Thus, there is some mechanism other than simple product inhibition by 
which insulin regulates hexokinase II activity. 
Glucose 1,5-diphosphate is an inhibitor of hexokinase II (76), 
and an activator of phosphofructokinase and pyruvate kinase (84). The 
possibility that this effector molecule plays a role in the regulation 
of substrate for glycolysis, i.e., from glycogen or from glucose direct­
ly, exists. Beitner has written a review on the role of glucose 1,5-di-
phosphate in muscle (84) and on the control of glucose 1,5-diphosphate 
levels (85). More recent studies from Beitner's laboratory (86) in­
dicate that hexokinase II which is first bound to the mitochondria is 
more susceptible to inhibition by glucose 1,5-diphosphate than the 
soluble enzyme. This is not in agreement with the mitochondrial bind­
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ing theory of insulin action which holds that binding to the mito­
chondria is a way to increase hexokinase II activity, not to decrease 
+2 . . 
the activity. However, the uptake of Mg is increased in response 
+2 
to insulin (87), and Beitner has shown that an increase in Mg renders 
the bound hexokinase II less susceptible to inhibition by glucose 1,6-
diphosphate (86). On the other hand Sprengers et al. (75) reported 
that bound hexokinase II is less inhibited by glucose 1,6-diphosphate 
+2 
with no effect of Mg . Whether control by glucose 1,6-diphosphate 
represents a physiologically important regulatory mechanism is not 
clear at this time. 
In 1966, Katzen (54) studied the effect of insulin on hexokinase 
II activity in the gastrocnemius muscle of the rat in more detail. He 
carried out a time course experiment on the restoration of hexokinase 
II activity following the administration of insulin to streptozotocin-
diabetic rats. He reported an initial effect within 30 minutes of 
treatment and peak levels within an hour. The duration of the insulin 
treatment lasted shortly beyond the peak and the activity fell to 
pre-treatment levels in another hour beyond the peak. The peak values 
never appeared to exceed normal values using the gel electrophoresis 
assay. The effect of insulin, given intravenously on hexokinase II 
appeared to be more rapid than the effect on glucokinase (22). Insulin 
has been shown to stimulate new glucokinase protein synthesis (9,10). 
This could account for the difference in the observed response time. 
However, the number of receptors or other differences in the mediation 
of these effects of insulin in different tissues, as well as the mode 
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and amount of insulin administered, could also account for the difference 
in response time. In many of these experiments these details are not 
reported. 
In 1965, Gromova and II'Yin (49) observed a very rapid rate of 
restoration of insulin in fasted rats but maximal values were not 
reached until four hours later, not one hour later as reported by 
Katzen. These investigators (49) also found that chloramphenical 
(a protein synthesis inhibitor) blocked the insulin restoration of 
hexokinase II in the fat pad. This was later confirmed by Hansen et al. 
(50). In this same study, Hansen et al. demonstrated that cyclo-
hexamide blocked the insulin stimulated hexokinase II activity vivo. 
These studies indicated that protein synthesis is involved in the 
action of insulin on hexokinase II. In a 1970 study, Hansen et al. (88) 
found that while insulin alone (no glucose necessary) increased hexo­
kinase II activity in fat pads vitro, the inclusion of actinomycin 
D blocked this increase. Taken together, these studies confirm that 
protein synthesis is involved in the action of insulin on hexokinase 
II. Since cyclohexamide blocks at the point of elongation, this does 
indicate that nova synthesis is involved in the increase. The 
blockage by actinomycin D supports the conclusion that new mRNA and 
subsequently new protein formation is involved in the increase in 
activity of hexokinase II in the fat pad. 
It has been shown that overall protein synthesis is impaired in 
the muscle of diabetic animals in vivo (89) nnd in perfused muscle (90), 
In general, insulin promotes the synthesis of enzymes involved in carbo-
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hydrate utilization and storage and represses the synthesis of enzymes 
involved in the synthesis of glucose (91). In the diabetic skeletal 
muscle, an overall increase in polysomal disaggregation is seen (92, 
93), which leads to an inhibition of peptide-chain initiation. There 
is a decrease in the total amount of RM (94,95) in the diabetic skel­
etal muscle as well. Studies on some enzymes have shown specific in­
creases in synthesis in response to insulin. Some of these enzymes 
for which the level of mRNA has been shown to increase in response to 
insulin are glucose 6-phosphate dehydrogenase (95), pyruvate kinase 
(97,98), tyrosine aminotransferase (99), and glucokinase (100,101). 
This suggests then that a decrease in the rate of synthesis could give 
rise, in part, to the decrease in measurable hexokinase II activity 
seen in the diabetic rat skeletal muscle. 
Studies by Hansen et al. (88) demonstrated that the incu­
bation of fat pads from starved rats with insulin did not tend to 
stabilize hexokinase II against degradation any more than that of the 
other cytosolic proteins. Numerous studies have shown that there is 
an increase in overall protein degradation in the diabetic state (see 
reference 102 for review). Investigators have shown that in normal 
cells large molecular weight proteins tend to be degraded more rapidly 
than small proteins (102-104), acidic proteins more rapidly than basic 
or neutral proteins (102,105), and glycoproteins more rapidly than non-
glycoproteins (105,107). These general correlations do not appear to 
hold in the muscle of the diabetic or starved rat. This then suggests 
that the general characteristics of intracellular protein degradation 
2'I 
are altered in the diabetic state. These are only generalities and so 
the assumption should not be made that a protein that turns over quickly 
in the normal muscle will not turn over rapidly in the diabetic muscle 
when compared to the total cytosolic proteins. Studies have shown an 
increase in muscle protein degradation of both lysosomal (108) and 
nonlysosomal (109) origin in the diabetic rat. 
Murakami and Rose (110) found that hexokinase II which had been 
inactivated at 30°C in low glucose buffer was more susceptible to 
inactivation by trypsin. They suggested that the low glucose concen­
tration in the cell in the diabetic state might lead to inactivated 
enzyme and hence to a form that is more rapidly destroyed i^ vivo. 
In 1983, Rose and Warms (111) looked at this instability of hexokinase 
II in more detail. They found that hexokinase II, which is readily 
oxidized in the absence of glucose vitro., is somehow stabilized in 
whole ascities tumor cells which are lacking in glucose. They found 
that while caused no change in the kinetic properties of hexokinase 
II, it did serve to stabilize the enzyme against thermal inactivation. 
Again, hexokinase II was stabilized against thermal inactivation by 
glucose and this stabilization was additive with both and glucose 
present. The binding of hexokinase II to the mitochondrial membrane 
also served to increase the thermal stability of the enzyme. Once 
oxidized, neither glucose nor k"*" had any effect in promoting the reacti­
vation of the enzyme. 
The glucose concentration and the concentration are both de­
creased in the muscle cell in the diabetic state. This then could lead 
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to a decrease in the stability of the enzyme. So, there is evidence to 
indicate that hexokinase II degradation may be increased in the diabetic 
rat skeletal muscle. 
There are many examples of the covalent modification of enzymes 
leading to a decrease or increase in the activity of pre-existing en­
zyme (see reference 112 for review). Covalent modification, particu-
larily phosphorylation, is known to be important as a cellular regula­
tory mechanism. Since epinephrine action is mediated by changes in 
enzyme phosphorylation (113,114).^ it does seem logical that insulin 
action in the muscle might also involve changes in the phosphorylation 
states of proteins. Pyruvate dehydrogenase (115,115), glycogen 
synthase (117,118), acetyl-CoA carboxylase (119,120), pyruvate kinase 
(121), 3-hydroxy-3-methylglutaryl-CoA reductase (122), and glycogen 
phosphorylase (123) are dephosphorylated in response to insulin. 
Ribosomal protein S6 (124,125) and ATP-citrate lyase (125,127) are 
phosphorylated in response to insulin. In addition, the activity of 
pyruvate dehydrogenase (115), glycogen synthase (118), glycogen phos­
phorylase (123), and pyruvate kinase (121) change concomitantly with 
changes in the phosphorylation state, Acetyl-CoA carboxylase has 
been shown to lose its dependence on citrate for activity once it is 
dephosphorylated (120). 
This thesis deals with the last three possible mechanisms of 
insulin action on hexokinase II, 1) if there is a change in the specif­
ic activity of hexokinase II, 2) if there is a change in the synthesis of 
hexokinase II, and 3) if there is a change in the rate of degradation 
of hexokinase II response to insulin. 
Approach to Studying an Altered Enzyme Level 
In 1935, Borsook and Keighley (128) proposed that in mammalian 
tissues all proteins are continually synthesized and degraded. In the 
late 1930s and early 1940s, studies from a number of research groups 
using isotope tracer techniques indicated that there is an active incor­
poration and release of isotope compounds from proteins of various 
tissues (see reference 129 for review). Since there is a continual 
synthesis and degradation of proteins, the level of a particular pro­
tein is a function of both the rate of synthesis and the rate of degra­
dation. Thus, a change in the level of an enzyme can be expressed (130) 
as in equation 1: 
i = "s- V 
where E is the amount of enzyme (units x mass ^), is the zero order 
—  1  — 1  
rate constant of synthesis (units x time x mass ), and k^ is the 
first order rate constant of degradation (time ^). In a steady state 
dE/dt equals zero such that 
k 
( 2 )  
^d 
We can see from this treatment that the amount of enzyme present is a 
function of both the rate of synthesis of the enzyme and the rate of 
degradation of the enzyme. such that an alteration in either rate can 
affect the amount of enzyme present, 
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The model presented is a simplified model in which the separate 
variables that determine the rate of synthesis of a specific protein 
are included in one constant, k . This is because not all the factors 
' s 
and contributions are known (129). Some of these factors include the 
number and efficiency of ribosoraes, the amount of mP.NA, the availability 
and regulation of initiation and transfer factors, the level of tRNA, 
and the levels of amino acids available. All these factors are included 
in the general term, rate constant of synthesis. 
The rate of degradation of a protein has been expressed as a 
first order rate constant. While there are exceptions to this, i.e., 
hemoglobin (131), the degradation of the majority of specific proteins 
studied have followed first order kinetics (129). One final note; 
there is no term included in equation 1 for a change in total mass of 
the tissue. This is because, generally, no total change occurs during 
the time period studied. 
When studying the mechanism for an altered level of enzyme, 
there are some questions to ask. The first question is whether the 
observed difference in measurable activity is a result of a difference 
in measurable activity of pre-existing enzyme (specific activity), or 
an altered content (amount) of enzyme, or both. Secondly, if there 
is a difference in the amount of enzyme protein, is this difference 
a result of an alteration in the rate of synthesis, the rate of deg­
radation, or both. 
It is essential to determine the specific activity of the enzyme 
being studied because of the many examples of the covalent modifica­
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tion of enzymes leading to a decrease or increase in the activity of 
pre-existing enzyme (112). To determine then precisely the factor(s) 
undergoing the alteration relative to the normal state in diabetes, 
it is essential that the specific activity of hexokinase II be accu­
rately determined. Measurements of hexokinase II activity have been 
accomplished by using activity stains on starch gels (17) or cellulose 
acetate (132), by differences in the thermal stability (58), or by 
corrections derived from kinetic differences of the isozymes of hexo­
kinase (133). In a recent report, Gudnason et al. (134) indicated 
that the tetrazolium dye staining technique for the detection of hexo­
kinase activity is relatively insensitive, therefore hexokinase activity 
is underestimated. In many studies, total protein, rather than hexo­
kinase II protein, has been used in specific activity determinations 
(135,135). So it is clear then, that a valid determination of hexo­
kinase II has not been reported. The protein amount of hexokinase II 
may be quantitatively determined by utilizing an enzyme-linked immuno­
sorbent assay, an ELISA. 
The ELISA was first described independently by two groups, Engvall 
and Perlmann (137) and Van Weeman and Schuurs (138). This is a hetero­
geneous enzyme immunoassay which is based on the same principles as the 
radioimmunoassay (RIA). There are many good reviews which cover this 
subject (139,140), and will not be discussed in detail in this thesis. 
The major difference between the ELISA and the RIA is that the ELISA 
does away with the need for a radioactive label and uses an enzyme 
activity label in its place. An enzyme is usually chosen which yields 
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a colored product and is thus easy to quantitate. 
The ELISAs' sensitivity, to is comparable to the 
RIA, and is really limited by the binding affinity between the antigen 
and the antibody. Direct comparisons of the RIA and the ELISA pro­
cedures have demonstrated that the two methods do have comparable sensi­
tivities (141,142). Interassay variation is reported to be between 
5-15% for the ELISA, which is, again, comparable to the RIA (140,141). 
The specificity of the ELISA is determined principally by the 
specificity of the antibody. However, the adsorption process itself 
is nonspecific. The protein is adsorbed to the plastic surface of a 
microtiter plate by hydrophobic interactions (140) and not linked by a 
covalent bond. This means not only that the adsorbed protein can be­
come unbound leading to a loss in precision, but also that during the 
incubation with the antibody, or the conjugate, these proteins can 
also be adsorbed onto the surface of the well. To help prevent the 
formation of these hydrophobic interactions between the surface of the 
well and the antibody and conjugate, a neutral detergent, such as 
Tween 20, is added. The concentration is kept low so as not to 
disrupt the hydrophobic bonds between the surface of the well and the 
previously adsorbed antigen. Provided these nonspecific interactions 
do not interfere with the quantification, the ease and rapidity of this 
method of separation of the antigen-antibody complex is advantageous 
over methods which utilize centrifugation for separation. 
The estimation of the apparent rate constant of degradation of 
hexokinase II can be approached using a double-isotope method as 
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described hy Arias et al, (143) and Glass and Doyle (1U4). In this 
method, two isotopic forms of an amino acid are used to establish time 
points on the curve which describes the degradation of the protein. 
This involves the administration of one isotopic form of an amino acid 
(^^C) initially. After allowing the labeled amino acid to be incorpo­
rated for differerent lengths of time, a second isotopic form of the 
amino acid is given. The animal is then sacrificed a short time fol­
lowing the administration of the second isotope. The ratio of 
to [radioactivity incorporated into a protein is then an indi­
cation (a reflection) of the proteins' rate of degradation. Proteins 
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that are degraded faster will have a high H/ C ratio as compared 
with those proteins which are degraded more slowly. This is a re­
flection of the increased loss of the label in proteins which are 
degraded faster. This method is useful in providing information about 
the general charateristics of protein degradation so as to allow the 
comparison between different physiological states. 
There are some assumptions involved with the use of this method. 
These assumptions include; a) the rates of synthesis and degradation 
must be the same when both isotopes are given, b) the radioactive amino 
acid used must not be metabolized to other compounds which are then 
incorporated into proteins, c) the protein must follow exponential 
decay kinetics, and d) at the time of sacrifice of the animal, the 
and must be on the exponential portion of the decay curve. 
For the most part, these have been shown to be valid assumptions 
for skeletal muscle proteins in the normal (143-147), diabetic. 
diabetic insulin-treated, and starved rat (145,147). Diurnal fluctua­
tions and differing adaptations to the disease state will affect assump 
tions (a) and (c). However, when looking at a pure protein, one can 
obtain exponential decay curves. When looking at a mixture of proteins 
this may not be the case due to the fact that different proteins will 
change at different rates and thus cannot be expected to average each 
other out to give a straight line on a log plot. Even with a mixture 
of proteins, the ratio of to [^^c] incorporation does reflect an 
average rate of degradation over the time interval studied. 
Assumption (b) appears to be valid for muscle proteins using 
leucine. Dice et al. (147) found that after injection of and 
[^^c] labeled leucine, essentially all of the radioactivity in the 
proteins was recoverable as leucine in the normal, diabetic, and 
diabetic insulin-treated rat skeletal muscle. 
Assumption (d) is not entirely valid since leucine is a re-
utilizable amino acid. Due to reutilization, the time it takes a 
protein to reach maximal labeling is also a function of its rate of 
degradation. Glass and Doyle (144) demonstrated experimentally that 
because of this the interval between the two isotope injections must 
be varied. Since reutilization of leucine may change during diabetes 
and starvation. Dice and colleagues (147,148) looked at the rates of 
degradation of proteins using Na^^CO^ as the first isotope and ["H]arg-
inine, asparigine, and glutamine as the second isotopes given. These 
amino acids are reutilized at a low rate (103,149). Employing SDS gel 
3 14 
electrophoresis, and comparing the H/ C ratios in differing molecular 
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weight bands, they obtained the same results using leucine. This 
suggests that the results using leucine are not due to artifacts asso­
ciated with reutilization. At any rate, meaningful comparisons can 
be made between the rates of degradation of different proteins or the 
same protein, provided they are determined with the same labeled pre­
cursor, and provided that the values obtained are considered as rela­
tive or apparent, rather than actual, or absolute, degradation rates. 
The estimation of the relative rates of synthesis can be ap­
proached utilizing a single injection of [^hJ leucine. The relative 
rate of synthesis can then be expressed as a percentage of incorpora­
tion of counts into a specific protein relative to the cytoplasmic 
proteins. This allows for any variability, not only of label injected, 
but also of pool size differences. In a recent study, Pomposelli et al. 
(150) compared different techniques for estimating rates of synthesis 
of proteins in various rat tissues, including skeletal muscle. They 
determined that both single dose methods and constant infusion methods 
are equally valid when used to determine relative rates of synthesis 
in order to compare these between different physiological states. It 
is also necessary to determine the relative rate of synthesis at several 
time points to be assured of maximal labeling in all disease states. 
Streptozotocin 
Type I diabetes mellitus, insulin dependent diabetes mellitus, 
can be induced by the injection of streptozotocin (151). Agarwal (152) 
has written an excellent review on streptozotocin, Streptozotocin is 
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a nitrosourea which induces irreversible degranulation of the pan­
creatic p-cell (153). Agarwal points out in his review article that 
streptozotocin produces a low fatality rate, is specific, and shows a 
lack of generalized cytotoxicity. Studies have shown that the disease 
state induced mimics type I diabetes mellitus (154) symptomatically, 
metabolically, and morphologically. In addition, Katzen et al. (57) 
have shown that streptozotocin itself does not interact with hexokinase 
II. Therefore, it appears that the diabetic state induced by strep­
tozotocin is a good model system for studying the effects of the 
diabetic state and insulin on the levels of hexokinase II. 
3 ' I  
MATERIALS AND METHODS 
Materials 
Nitrocellulose, BA, pore size was supplied by Schleichter 
and Schuell. Immulcn II polystyrene microtiter plates were purchased 
from Dynatech Laboratories, Inc. Streptozotocin, goat anti-rabbit IgG-
alkaline phosphatase conjugate, jg^-nitrophenylphosphate (Sigma 104), 
bovine serum albumin (essentially fatty acid and immunoglobulin free), 
and Tris base were purchased from Sigma. Pansorbin (10% w/v Staph-
lococcus aureus cell suspension) was purchased from Calbiochem. Lente 
insulin (Squibb), Ketostix (Ames Division of Miles Laboratories), and 
Chemstrip Bg (Boehringer Mannheim) were supplied by a local drug 
store. White, male Wistar rats were obtained from Hilltop Laboratories. 
L-[4,5-^h]leucine (65mCi/mg) and L-leucine (300Ci/mol) were 
purchased from Amersham. Frotosol was supplied by New England Nuclear. 
Insulin RIA kit was obtained from Radioassay Systems Laboratories, Inc. 
Distilled, deionized water wcs used for the preparation of all reagents. 
All other chemicals were of the highest purity commercially available. 
Methods 
Animals 
White, male Wistar rats weighing 180-200g were used in this 
study. The rats were caged individually under controlled conditions 
(22°C room temperature, controlled humidity, light cycle 12 hour/12 
hour). After housing for one week, the animals were used in the study. 
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The diabetic state was induced by intravenous injection of streptozo-
tocin, 75mg/kg body weight, following a 24-hour fast (151). The stock 
solution for injection contained 0,14H streptozotocin, 50mM citric 
acid (pH 4.5), and 0.9% NaCl. The rats received 10% glucose water for 
24-hours to counteract the insulin spike seen when the -cells are 
destroyed and the insulin contained in them released (151). Control 
animals received an intravenous injection of 50mM citric acid (pH 
4.5) and 0.9% NaCl after a 24-hour fast. Blood glucose was monitored 
daily as was the weight of the animal. After 4-5 days, the blood 
glucose levels of the streptozotocin treated animals were above 40Gmg/ 
100ml. At this point, these rats were considered diabetic. The 
diabetic, as well as the normal rats, were now used for experimentation. 
Some of the diabetic rats received a daily injection of 1.5 U Lente 
insulin/lOOg body weight. This treatment was continued for 5-7 days. 
Blood glucose and body weight were monitored daily. 
Food was taken away from those animals involved in the synthesis 
and specific activity studies 3 hours prior to the experiment. These 
experiments were started between 10 AM and noon. For animals involved 
in the degradation studies, where one label is allowed to incorporate 
for much longer time periods (12-36 hours), the animals were sacrificed 
at different times of the day. In an attempt to average out these 
differences, duplicate experiments were started at different times, one 
set between 9 AI' and 11 AM and the other between 9 PK and 11 PM. 
Animals were allowed free access to food. Animals were sacrificed by 
severing the vena cava while under light ether anesthesia. 
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Enzyme purification 
Hexokinase II was purified from rat skeletal muscle by the method 
of Qadri and Easterby (155). The enzyme was stored in 0.2M phosphate 
buffer, pH 7, 0.2M KCl, 5mH EDTA, and 2 mM DTT. The enzyme was judged 
pure by native (155,157) and SDS (158) gel electrophoresis. The correct 
identity of the hexokinase II was confirmed by kinetic analysis (37). 
Enzyme activity assay 
Total hexokinase II activity in the extracts was determined 
utilizing a glucose 5-phosphate dehydrogenase coupled assay (159). 
The standard assay contained 20mM HEPES buffer (pH 8), 3mM glucose, 
lOmM ATP, lOmM KgCl^, 0.4mM NADP"*", and 0.5 units glucose 6-phosphate 
dehydrogenase in a total volume of one ml. One unit of activity is 
defined as one pmol glucose 6-phosphate produced per minute at 28°C. 
Blood glucose determination 
Blood glucose was determined on a daily basis by using a 
Chemstrip Bg for glucose in whole blood and for experimentation by 
using a hexokinase/glucose 5-phosphate dehydrogenase coupled assay 
(150). The assay contained 20rnM HEPES buffer (pH 8), lOmM ATP, lOmK 
MgCl^, and O.UmM NADP* in a total volume of one ml. 
Serum ketone levels 
Serum ketone levels were tested using a Ketostix reagent strip 
which detects acetoacetic acid. 
Insulin determination 
Serum insulin was determined using an insulin RIA kit (161). 
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Protein assay 
Protein was assayed according to the method of Bradford (162). 
Antibody production 
Antibodies to rat skeletal muscle hexokinase II were raised in a 
New Zealand white rabbit (male) by subcutaneous injection of 200jig of 
hexokinase II in Freunds' incomplete adjuvant. Additional injections 
were made 14, 28, and 50 days later. Antisera were obtained 7 and 9 
days following the final boster. After collection of the blood by 
heart puncture, the blood was allowed to clot at room temperature. 
Red blood cells were removed by cetrifugation at 5000 x g_. Serum was 
heated to 56°C for 20 minutes (153), spun at 25,000 x g_to separate 
lipids, and filtered through glass wool. The serum was partially 
purified by ammounium sulfate precipitation (163). The serum was 
stored in lOmM phosphate buffer with 0.02% NaN^ at either 4°C or at 
-20°C. Control serum was treated in the same manner. 
Assays for the selectivity of antisera 
The antisera against hexokinase II were tested by two different 
methods, Ouchterlony double-diffusion and western blotting. Thin-layer 
Ouchterlony double-diffusion analysis was carried out on 1% agarose 
plates (15U). 
The antisera were also tested by a modification of the western 
blotting technique of Towbin et al. (165). Purified hexokinase II, puri­
fied hexokinase I, and muscle extracts were subjected to electrophoresis 
(7% native polyacrylamide gels) and transferred to nitrocellulose paper. 
The assay was completed by two separate methods. The first method 
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ultimately detects the antigen-antibody reaction with [ ^^^ijprotein A, 
and the second method by an enzyme-second antibody conjugate. 
In the first method, unoccupied sites on the nitrocellulose were 
blocked with 3% BSA in a lOwM Tris-Cl buffer, pH 7.1, containing 0.9% 
NaCl and 0.04% NaN^ at 4°C overnight. After being washed with buffer 
A (50mM Tris-Cl, pH 7.4, 150mM NaCl, 5mM EDTA, 0.25% gelatin, 1% BSA, 
and 0.04% NaK^), the antisera, diluted in this same buffer, were added 
to the nitrocellulose. The nitrocellulose was then incubated with gentle 
shaking for 4 hours at 37°C, washed with buffer A, and incubated an­
other hour in buffer A at 37°C. After being washed with buffer A, the 
nitrocellulose was incubated with 10 pCi protein A in 3 ml buffer 
A for 3 hours, with gentle shaking, at 37°C. The nitrocellulose was 
then washed with 50mM Tris-cl buffer, pH 7.4, containing linM NaCl, 
0.4% Triton x-100, 5mM EDTA, 0.25% gelatin, and 0.04% NaN^, This was 
followed by washing with water. The nitrocellulose then was allowed 
to dry, after which it was autoradiographed. 
In the second method, unoccupied sites on the nitrocellulose 
were blocked with 3% BSA in buffer B (0.14M NaCl, l.SmM KHgPO^, 8mM 
NagHPO^, 2.7mK KCl, 0,02% HaN , and 0.05% Tween 20, pH 7.4) at 4°C 
overnight. After being washed with buffer B, the antisera, diluted in 
this same buffer, were added to the nitrocellulose. The nitrocellulose 
was then incubated with gentle shaking for 4 hours at room temperature, 
washed with buffer B, and incubated another 0,5 hours in buffer B, 
After being washed with buffer B, the nitrocellulose was incubated with 
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goat anti-rabbit IgG-alkaline phosphatase conjugate in buffer B for 
4 hours. After being washed with buffer B, the nitrocellulose was 
incubated 0.5 hours with buffer B, followed by a 0.5 hour incubation 
with substrate solution (155), containing O.USmM MgClg, 0.1% nitroblue 
tetrazolium, O.Smg 5-bromo-4-chloroinoxyl phosphate in 10% diethanol-
amine buffer, pH 8.9. The reaction was terminated by washing with 
water. 
Enzyme-linked immunosorbent assay (ELISA) 
Purified hexokinase II and muscle extracts were diluted in 
coating buffer, 0.02M Na^CO^, 0.03M MaHCD^, 0.02% NaN^, pH 9.6. 
Known amounts of purified hexokinase II, dilutions of the muscle extracts 
or coating buffer alone were added to the polystyrene microtiter plates 
in a total volume of 0.2 ml per well, and the plates were placed in a 
humid chamber at 4°C. After 18 hours, the plates were washed by filling 
the wells with PBS-Tween 20 (157) from a wash bottle and incubating for 
5 minutes. This process was repeated three times. After the addition 
of 0.2 ml of 1% BSA in PBS-Tween 20 to each well, the plates were incu­
bated in a humid chamber at 4°C for 12 hours. The plates were washed 
as before, followed by the addition of 0.2 ml of anti-rat hexokinase 
II or control sera to the wells. Dilutions of the anti-rat hexokinase 
II and control sera were made in PBS-Tween 20, 1% BSA. The plates 
were then incubated in a humid chamber at room temperature (23 C) for 
2.5 hours. The plates were then washed again as indicated, and 0.2 ml 
of goat anti-rabbit IgG-alkaline phosphatase conjugate, diluted in 1% 
BSA in PBS-Tween 20, was added to each well. The plates were incubated 
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.in a humid chamber at room temperature for 2.5 hours. Following the 
washing of the plates as suggested, 0.2 ml of alkaline phosphatase sub­
strate containing Img/ml jD-nitrophenylphosphate and 0.5mM MgCl^ in 10% 
diethanolamine buffer (pH 9.8). After 30 minutes the reaction was ter­
minated by the addition of 0.1 ml of 3M NaOH, The absorbance was read 
at UOOnm (168). 
Immunoprecipitation of hexokinase II 
Skeletal muscle (gastrocnemius and quadriceps) was extracted in 
50mM Tris-CL, pH 7.4, 0.15M NaCl, 5mM EDTA, O.IM KCl, 0.02% NaN^, 0.05% 
Triton x-100 (19), and 5mM 2-mercaptoethanol by homogenization for 2 
minutes in a Waring blender. The homogenate was centifuged at 10,000 
x ^  for 30 minutes. Aliquots of the supernatant fluid, 0.3 ml, were 
incubated with 0.1 ml of control sera at ^°C for 1 hour. Following the 
addition of 0.5 ml of S. aureus (Pansorben), the samples were incubated 
for 1 hour at 4°C. The samples were centrifuged at 2500 x _g for 15 
minutes at U°C. To the supernatant fluid, 0.15 ml of anti-rat hexo­
kinase II was added. After incubation at for 12 hours, 0.05 ml 
S. aureus was added, and the samples were incubated another 2 hours. 
The samples were then centrifuged as before. The supernatant fluid 
contained no hexokinase II activity at this point. This was confirmed 
by repeating the above procedure on the supernatant fluid and by the 
ELISA procedure using the supernatant fluid as sample. 
Determination of counts incorporated into hexokinase II 
One tenth ml control sera was added to 0.3 ml aliquots of 
muscle homogenates. The samples were incubated at 4°C for 30 minutes. 
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followed by the addition of 0.5 ml S. aureus. After incubation at 4°C 
for 1 hour, the samples were centrifuged for 15 minutes at 2500 x _g. 
The precipitate was saved for radioisotope counting (pre-precipitate). 
To the supernatant fluid, 0.15 ml of rabbit anti-rat hexokinase II was 
added, followed by incubation at for 12 hours. To each sample, 
0.05 ml S. aureus was added, followed by incubation at 4°C for 2 hours. 
After centrifugation for 15 minutes at 2500 x the immunoprecipitate 
was saved for radioisotope counting. Either additional antisera or 
unlabeled hexokinase II plus more antisera were added, and the samples 
were treated as described above. The precipitates were saved for 
radioisotope counting. The addition of extra antisera was to ensure 
complete precipitation of hexokinase II in all samples. The unlabeled 
hexokinase II and antisera addition was carried out to determine if 
nonspecific trapping occurs. 
The precipitates were prepared for counting by washing three 
times with 0.15N NaCl containing 0.05% Triton x-100, followed by the 
addition of 0.05 ml water and 0.4 ml Protosol. The samples were incu­
bated at 37°C until the precipitate was dissolved. The samples were 
then taken up in 20 ml of a toluene scintillation mixture (2,5-di-
phenyloxazole, p^-bis[2-(5-phenyloxa2olyo)]-benzene). After sitting in 
the dark for 24 hours, radioactivity was counted in a Packard scintil­
lation counter. Sufficient radioactivity was counted to give a count­
ing error of 4% or less. All measurements were done in triplicate. 
'12 
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Channels were chosen such that there were no H counts in the C 
lU 3 
channel and approximately 5% C counts in the H channel. Efficiency 
was determined with an external standard. 
Determination of counts incorporated into cytosolic proteins 
To 0.3 ml aliquots of muscle extracts, 0.6 ml of TCA were added. 
The pellet was washed with 12% TCA, and another 0.6 ml 
12% TCA was added. The samples were incubated at 90 C for 15 minutes 
to dissolve nucleic acids. The pellets were then washed once with 95% 
warm ethanol and twice with a warm ethanol: ether : chloroform (2:2:1). 
The pellets were finally washed with warm ether and allowed to air dry 
(169). The samples were prepared and counted as described for the 
immunoprecipitates. 
Determination of synthesis rate 
L-[4,5-^H]leucine (0.9mCi/100 grams of body weight) was adminis­
tered by intraperitoneal injection at zero time. After exposure to 
the label for the specified times, the animals were sacrificed. 
Skeletal muscle was dissected form the hind legs and homogenized as 
described under "Immunoprecipitation of hexokinase II". 
Determination of enzyme degradation 
L-[u-^^c]leucine (13uCi/100 grams of body weight) was adminis­
tered by intraperitoneal injection at zero time. Additional injections 
of L-[''+,5-'^Hjleucine (25uCi/100 grams of body weight) were given 
12, 24, and 36 hours later. After exposure to the label for one 
hour, the animals were sacrificed. Skeletal muscle was dissected from 
the hind legs and homogenized as described under "Immunoprecipitation 
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of hexokinase II". 
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From the estimated H/ C ratios measured in the hexokinase II 
immunoprecipitate, the apparent rate constant of degradation was 
calculated according to the following equation (144): 
X log 
0 t 
(3) 
The apparent half-life of the hexokinase II was calculated from the 
following relationship: 
These same calculations, using equations (3) and (4), were carried out 
for the total cytosolic proteins also. 
SDS gel electrophoresis of iimnunoprecipitates 
Two tenths of a ml of lOmM phosphate buffer, pH 7, containing 2% 
SDS, 2% 2-niercaptoethanol, O.IM glucose, and 0.05% bromophenyl blue was 
added to the immunoprecipitates and the hexokinase II standard. These 
samples were then boiled for 5 minutes. The samples were run on a SDS 
gel (158). One gel was stained with coomassie blue, while the duplicate 
gel was cut. The cut gel was dissolved in 0.2 ml water and 0.6 ml 
Protosol at 50 C for 2-3 days. The samples were then counted as 
described under "Determination of counts incorporated into hexokinase 
II". Pure hexokinase II was run and stained with coomassie blue as a 
standard. 
Statistics 
Statistical difference was tested using the student's t-test (170). 
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RESULTS 
Animals, Antisera, and Assays 
Enzyme purification 
Hexokinase II was purified to a specific activity ranging from 
100 units/mg protein to 176 units/mg protein. The enzyme was judged 
pure by native and SDS polyacrylamide gel electrophoresis, One band 
was seen in both gel systems as shown in Figure 2. The identity of the 
hexokinase II isozyme was confirmed by kinetic analysis. Orthophos­
phate did not relieve the mannose 6-phosphate inhibition of the enzyme, 
indicating that the enzyme was not hexokinase I. The possibility 
that the hexokinase represented hexokinase III was ruled out by the 
lack of inhibition of the enzyme activity at 3mM glucose. Since the 
enzyme was active at 3mM glucose and only one band was seen upon elec­
trophoresis, the possibility that the enzyme represented hexokinase 
III was ruled out. 
Animals 
Serum glucose, insulin, and ketone body levels, as well as the 
weight loss or gain, and the mg soluble protein per gram muscle are 
summarized in Table I. The animals represented in this summary are 
those that did not receive radioactive amino acids. The diabetic 
animals lost weight, an average of 2.9%/day, while both the normal and 
diabetic insulin-treated animals gained weight, 6.7% and 5.7%/day, 
respectively. The weight gain of the insulin-treated rats was calcu­
lated by using the weight gain after the start of insulin therapy. 
Figure 2. Native and SDS gel electrophoresis of purified hexokinase II 
from rat skeletal muscle. Shown are native gels of (a) 
50 ng, and (b) 25 fig hexokinase II, and SDS gel (c) of 
100 fig hexokinase II 

Table I. Profile of normal, diabetic, and diabetic insulin-treated rats 
Parameter Normal Diabetic Insulin-treated 
Weight gain (+) or loss (-) 46.7+1.5%(20)*'b -2.9±1.5%(19) +5.7+1.2%(23)b 
Blood glucose (mg/lOOml) 143±8(19)b 643±14(20) 112±7(23)^ 
Ketone levels (mg/lOOml)'" negative 15 trace 
Immunoreactive Insulin (|iU/ml) 53+2(12)^ 4+1(12) 31±4(14)^ 
Soluble protein (mg/g muscle) 76.9±5.1(19) 67.5+5.4(20) 66.1±5.4(23) 
^Values in parentheses represent number of animals and numbers represent average ± stan­
dard deviation. 
c 0.005 versus diabetic. 
^Approximate values are presented taken from test strips. See "Methods". 
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Serum glucose levels of the diabetic insulin-treated rats were lowered 
to approximately those levels found in the normal animals. In all 
animals used as diabetic, the serum glucose levels were above UOOmg/ 
100ml and the average was 643mg/100ml. The levels of insulin in the 
diabetic animals were negligible. The levels in the diabetic insulin-
treated rats were significantly higher than those found in the diabetic 
rat. The insulin levels found in normal rats were also significantly 
higher than those levels found in the diabetic animals. These values 
are in good agreement with those obtained by other investigators (171-
173). 
Chen and lanuzzo (173) saw no significant difference in the 
soluble protein content per gram muscle between the normal, diabetic, 
and diabetic insulin-treated rat. Their studies involved the gastro­
cnemius, plantaris, and soleus muscles in separate determinations. 
This same relationship was obtained in this study using the gastro­
cnemius and the quadriceps. In the early stages of diabetes there is 
a larger decrease in total soluble protein. As the diabetes progresses, 
there is synthesis of some proteins at the expense of other proteins, 
i.e., structural and contractile proteins (173). Therefore, the small 
decrease in soluble protein obtained is not unreasonable. The levels 
of ketones obtained in the study presented here are in agreement with 
those found in other studies (173). 
Selectivity of antisera 
The antisera were first tested using the Ouchterlony double-
diffusion technique (Figure 3). Only one precipitin line was seen 
Figure 3. Ouchterlony double-diffusion. 
Gel A; Well (a) contains normal rat skeletal muscle extract, 
wells (b)-(e) contain anti-rat hexokinase II, and 
wells (f) and (g) contain control sera. Well (h) 
contains purified hexokinase II, wells (i)-(l) 
contain anti-rat hexokinase II, and wells (n) and 
(m) contain control sera. 
Gel B; Well (a) contains purified hexokinase I and wells 
(b)-(g) contain dilutions of anti-rat hexokinase II. 
Well (h) contains diabetic rat skeletal muscle ex­
tract and wells (i)-(n) contain dilutions of anti-
rat hexokinase II. Well (o) contains control sera, 
wells (p)-(o) contain dilutions of diabetic rat 
skeletal muscle extract, and wells (u) and (t) 
contain purified hexokinase II. 
Gel C; Well (a) contains diabetic insulin-treated rat 
skeletal muscle extract, wells (b)-(e) contain 
dilutions of anti-rat hexokinase II and wells (f) 
and (g) contain control sera 
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against pure hexokinase II and muscle extracts from normal, diabetic, 
and diabetic insulin-treated rats. No precipitin line was seen against 
pure hexokinase I. In addition, no precipitin line was seen when pre-
immune sera were used. 
The antisera were then tested using the western blotting tech­
nique (Figure Ua). Only one reacting band was seen with muscle extracts 
from normal, diabetic, and diabetic insulin-treated rats which corre­
sponds to pure hexokinase II, No reaction was seen with pure hexo­
kinase I. The western blot assay was also repeated under conditions 
which mimic the ELISA assay (Figure 4b). Again only one band was seen 
with all muscle extracts and no band was seen with hexokinase I. The 
bands are streaked in the extracts as well as in the lane which contains 
pure hexokinase II. The use of a gradient gel gave no better resolu­
tion of the protein bands. 
The antisera were tested utilizing radiolabeled muscle ex­
tracts. The pre-precipitates from muscle extracts of normal, diabetic, 
and diabetic insulin-treated rats showed no significant counts above 
background. These were routinely tested on all samples. Examples of 
these can be found in Table II. 
After precipitation of labeled hexokinase II with antisera, a 
second precipitation with antisera was carried out to ensure total 
precipitation of the hexokinase II in the extracts. This was done 
routinely. Upon the addition of unlabeled hexokinase II plus add­
itional antisera, after prior precipitation of labeled hexokinase II, 
essentially no counts above background were precipitated. Examples 
Figure 4. Western blot assay. Plate A represents assay using 
[^^^ijprotein A to detect the antigen-antibody reaction. 
Assay of hexokinase I (HK I), hexokinase II (HK II), and 
muscle extracts from normal (N), diabetic (D), and dia­
betic insulin-treated (DI) animals. Plate B represents 
assay using IgG-alkaline phosphatase detection of the anti­
gen-antibody reaction. Assay of muscle extract from 
normal (a), diabetic (b), and diabetic insulin-treated (c) 
animals, and hexokinase I (d), and hexokinase II (e) 
53 
HK D HK N Dl HK 
I II I 
B 
DU 
Table II. Antibody specificity utilizing radioactive immunoprecipitates 
Animal ImmunopptPreppt.^ Second ppt.^ Second ppt. plus 
unlabeled enzyme 
Normal 179+17 4±2 1+1 0±0 
Diabetic 72+3 4±2 5+1 3±1 
Diabetic-insulin 146±9 2±2 7+1 2±2 
^Immunoppt. = immunoprecipitate; Preppt. = pre-precipitate; 
Second ppt. = second precipitate. 
^Numbers represent average cpm/g muscle ± standard deviation 
for triplicate analysis from three rats. 
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of this can be found in Table II. While this does indicate that non­
specific trapping is not a problem, it does not eliminate the possibility. 
As another test to detect this phenomenon, SDS gels were run on the 
immunoprecipitates. The gel profiles of the radioactive immunopre-
cipitates can be seen in Figure 5. The major peak of radioactivity 
corresponds to the hexokinase II. Since hexokinase I, II, and III 
are of the same molecular weight, this technique cannot distinguish 
between these enzymes. However, the western blot showed no reaction 
with hexokinase I, and only one band with the extracts, so it is un­
likely that hexokinase I or III account for the radioactivity in the 
immunoprecipitates. 
ELISA assay of hexokinase II protein 
In order to use an ELISA procedure for protein quantification, 
the primary antibody must be selective for a single protein. This 
selectivity is indicated by reference to the Ouchterlony double-
diffusion (Figure 3) and the western blot tests (Figure 4). Since 
only one reacting band was seen with muscle extracts from normal, 
diabetic, and diabetic insulin-treated rats, one would expect the ELISA 
procedure to be selective for hexokinase II. Possible nonspecific 
interactions in the ELISA method include those between the primary 
antibody and the microtiter well or adsorbed protein, other than 
antigen, coating the well. Also included are possible nonspecific 
interactions between the anti-rabbit IgG-enzyme conjugate and the 
microtiter well or adsorbed protein coating the well. To test this, 
controls which omitted the antigen, anti-hexokinase II antisera, or 
Figure 5. SDS gel profiles of iminunoprecipitates of labeled muscle 
extracts from normal (a), diabetic (b), and diabetic 
insulin-treated (c) rats 
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both were included. These wells did not give absorbance values greater 
than wells in which control sera were used. This indicates a lack of 
nonspecific interactions which could interfere with the assay. 
The use of the ELISA procedure for quantification in the 
muscle extracts depends also upon the establishment of a linear re­
lationship between the second antibody-enzyme conjugate and the anti­
gen. A linear relationship was found over a range of dilutions as 
depicted in Table III and Figure 6 for muscle extracts from normal, 
diabetic, and diabetic insulin-treated rats. Triplicate analysis 
routinely gave coefficients of variation within 10%. The validity of 
the ELISA procedure is also confirmed by testing for the recovery of 
the antigen in tissue extracts. Hexokinase II was determined in 
muscle extracts either directly or following the addition of pure 
hexokinase II. After analysis of both extracts, the percentage of 
recovery can be calculated as shown in Table IV. These results demon­
strate that the ELISA procedure developed is quantitative for hexo­
kinase II. It also demonstrates the specificity of the detection of 
hexokinase II in the presence of other cytosolic constituents in the 
muscle extracts. 
The amount of hexokinase II present in the muscle extracts was 
routinely determined by including a standard curve using pure hexo­
kinase II on each plate as well as dilutions of the muscle extracts. 
The standard curve was plotted as absorbance versus ng of hexokinase II 
per well. A representative standard curve is shown in Table V and in 
Figure 7. The amount of hexokinase II in the extracts was determined 
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Table III. Titration of muscle extracts utilizing the ELISA procedure 
Animal -1 Dilution 
°°400' CV(Z)b 
Normal 0 .02 0. 057 7 
0 .05 0. 110 5 
0 .075 0. 173 8 
0 .1 0. 225 3 
Diabetic 0 .02 0. 026 4 
0 .05 0. 060 3 
0 .075 0. 120 8 
0 .1 0. 150 8 
0 .13 0. 186 7 
Diabetic-insulin 0 .025 0. 038 5 
0 .05 0. 072 4 
0 .075 0. 107 6 
0 .1 0. 142 5 
0, .125 0. 176 6 
^Numbers represent the average of triplicate analysis. 
^CV represents the coefficient of variation. 
Figure 6. Titration of muscle extracts utilizing the ELISA procedure. Shown are titration 
curves of muscle extracts from normal ( x ), diabetic ( A ), and diabetic insulin-
2 treated ( • ) animals. Correlation coefficients for the curves are r = 0.99 for 
2 2 the normal, r = 0.99 for the diabetic, and r = 0.99 for the diabetic insulin-
treated animals 
0.05 
dilution' 
0.1 
a b 
Table IV. Recovery of hexokinase II in the ELISA procedure ' 
Animal ng Hexokinase Il/well Recovery 
muscle extract pure enzyme extract + enzyme (%) 
added experimental calculated C ^ j^qq 
(A) (B) (C) (A+B) A+B 
Normal 3.54 10.05 12.25 13.59 90 
7.17 20.11 26.33 27.28 96 
Diabetic 3.67 10.05 13.17 13.72 96 
6.83 20.11 28.58 26.94 94 
Diabetic-insulin 4.17 10.5 14.29 14.67 97 
4.17 21.1 21.67 25.18 86 
^Numbers represent the average of triplicate analysis. 
^Coefficients of variation are within 10% for all analysis. 
^As determined by the ELISA procedure. 
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Table V. Hexokinase II standard curve utilizing the ELISA procedure 
ng hexokinase Il/well 
°»400* CV(%)^ 
47.2 0.577 5 
35.2 0.458 4 
17.6 0.299 5 
8.8 0.145 5 
4.4 0.087 5 
2.2 0.055 6 
^Numbers represent triplicate analysis. 
CV represents the coefficient of variation. 
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Figure 7. Hexokinase II standard curve utilizing the ELISA procedure. 
2 Equation of the line: y = 0.012x + 0.034 r =0.99 
Points are graphed as mean ± standard deviation 
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from this standard curve. The results of these determinations can be 
found in Table VI. The amount of hexokinase II in the normal muscle 
was found to be approximately twice that in the diabetic muscle. Upon 
treatment with insulin, the amount of hexokinase II approached, but 
did not quite equal the levels found in normal animals. The amount 
of hexokinase II in normal tissue was found to be approximately 1.3 
times that in the diabetic insulin-treated animals. The amount of 
hexokinase II in the insulin-treated animals was approximately twice 
that found in the muscle of the diabetic animals. It is clear then, 
that in the diabetic state, the amount of hexokinase II protein does 
decrease, and treatment with insulin does increase the amount of hexo­
kinase II protein. This change in the amount of protein of hexokinase 
II protein may not be accounted for by a change in the specific 
activity of hexokinase II. To determine if there is a change in the 
specific activity, we measured the activity of hexokinase II in the 
muscle extracts form normal, diabetic, and diabetic insulin-treated 
rats. 
Immunotitration of hexokinase II (determination of hexokinase II 
activity 
The skeletal muscle of the rat contains hexokinase I, II, and 
III. Although our assay precludes the measurement of hexokinase III 
activity due to inhibition by glucose (39), it does measure both hexo­
kinase I and hexokinase II activities. To obtain the activity of only 
hexokinase II, the total activity in the extracts was measured (hexo­
kinase I and II), followed by the immunoprecipitation of hexokinase 
Table VI. Determination of hexoklnase II protein, activity, and specific activity in muscle 
extracts^ 
Animal mg hexoklnase II U hexoklnase II U hexoklnase II 
g muscle g muscle mg hexoklnase II 
Normal 5.86xl0~^±0.33xl0"^^ 1.38±0.17 237±23 
Diabetic 2.46xl0~^±0.18xl0~^ 0.61±0.08 248+28 
Diabetic-insulin 4.66x10 ^±0.56x10 ^  1.14±0.14^ 246±39 
^Values presented are means ± standard deviation for triplicate analysis of samples from 
7 rats. The specific activity was calculated as the mean of the 7 specific activity values from 
the 7 animals. 
^P<0.005 versus diabetic. 
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II with antibody. The remaining measurable activity in the supernatant 
fluid (hexokinase I) was assayed after immunoprecipitation. The activity 
of hexokinase II was calculated as the difference in activity before 
and after immunoprecipitation. Control sera did not precipitate any 
hexokinase activity, as shown in Table VII. 
Immunotitration curves of muscle extracts from normal, diabetic, 
and diabetic insulin-treated rats with antisera are illustrated in 
Figure 8. It can be seen that the extracts reach a constant amount 
of measurable hexokinase activity, which is in fact, hexokinase I 
activity. If hexokinase I is added to these extracts, no additional 
activity is precipitated with antisera. This indicates that the hexo­
kinase I activity was not precipitated in this system. After immuno­
precipitation using 0.15 ml of antisera, the supernatant fluid was 
analyzed for remaining hexokinase II protein by the ELISA procedure 
described earlier. No hexokinase II protein was found in the super­
natant fluids. 
The titration curves also indicate that equal amounts of antisera 
do not precipitate equal percentages of total hexokinase activity. 
This is due to differences in the amount of hexokinase II activity in 
the skeletal muscle in the different hormonal states of the animals. 
The results of the determinations of measurable hexokinase II activity 
in the various samples can be found in Table VI. The activity in the 
normal animals is approximately 2.3 times that in the diabetic animals. 
Again, upon treatment with insulin, the activity of hexokinase II 
approaches normal but does not quite equal the levels found in normal 
G a 
Table VII. Reaction of hexokinase II in muscle extracts with control 
a 
sera 
before (%) after (%) 
precipitation precipitation 
Normal 0.142 3 0.145 2 
Diabetic 0.135 2 0.133 2 
Diabetic-insulin 0.133 3 0.131 2 
rats. 
^CV represents the coefficient of variation. 
Figure 8. Immunotitration curves of skeletal muscle extracts from normal (a), diabetic (c), and 
diabetic insulin-treated (b) rats. Points represent the average of triplicate analysis 
of samples from three animals 
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animals. The activity in the muscle from normal animals is approxi­
mately 1.2 times that in the insulin-treated animals. The activity in 
the muscle extracts of the insulin-treated animals is also approxi­
mately 1.9 times that in the diabetic animals. This decrease in hexo-
kinase II activity in the diabetic state is in agreement with many 
other investigations in which a similar decrease of hexokinase II 
activity in the diabetic state, and an increase in hexokinase II activ­
ity upon treatment with insulin, has been reported (22,57). 
Determination of the specific activity of hexokinase II 
The specific activity of hexokinase II can now be calculated 
from the data obtained thus far. From the amount of hexokinase II 
protein, as determined by the ELISA procedure, and the activity of 
hexokinase II, as determined by immunoprecipitation, the specific ac­
tivity of hexokinase II can be calculated. The specific activity is 
expressed as units of hexokinase II activity per mg hexokinase II 
protein as shown in Table VI. The specific activity of hexokinase II 
is the same in the skeletal muscle extracts from normal, diabetic, and 
diabetic insulin-treated rats, even though the amount of hexokinase II 
protein is not the same in these different physiological states. 
Preliminary degradation and synthesis studies 
Preliminary degradation studies at three different doses of 
labeled leucine were carried out to ensure that the apparent rates of 
degradation obtained were not a function of the dose of labeled amino 
acid given. The results of these preliminary studies are summarized 
in Table VIII. At all levels of leucine the apparent rate of dégrada-
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Table VIII. Preliminary degradation studies on hexokinase 11^ 
Animals 
jiCi 
Labeled 
/lOOg 
Leucine 
MCi 
111 
c /lOOg 
Time^ 
(hr) (hr) 
Normal 32 13 12 25 
26 13 24 27 
68 25 21 26 
Diabetic 26 13 12 7 
26 13 24 9 
60 20 12 8 
68 25 20 10 
^Each point represents the average of triplicate analysis of 
iramunoprecipitates from two rats. 
^Time of exposure to the label. 
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t.ion of hexokinase II in the diabetic rat was approximately 3 times 
that found in the normal rat, which indicates that the results obtained 
are not dependent upon the amount of labeled leucine given. 
The results of the preliminary synthesis studies are shown in 
Table IX. The time of incorporation of label is one hour. The rela­
tive rates of synthesis were the same at both levels of leucine 
given. This indicates that the relative rates of synthesis obtained 
are not dependent upon the amount of leucine given. 
Synthesis of hexokinase II and total cytosolic proteins 
Hexokinase II synthesis was measured in normal, diabetic, and 
diabetic insulin-treated rats. This data can be found in tabular form 
(Table X) as well as graphical form (Figure 9a). Synthesis was also 
measured for the total cytosolic proteins and this is found in Table 
X and Figure 9b. From the slope of the line, the rate of synthesis is 
expressed as dpm incorporated per mg muscle per hour. The rate of syn­
thesis of hexokinase II in normal rat skeletal muscle is 5.24 dpm 
per mg muscle per hour; for the diabetic, 1.85 dpm per mg muscle per 
hour; for the insulin-treated, 5.10 dpm per mg muscle per hour. The 
rate of synthesis is thus approximately 2.8 times greater in the 
normal state as compared to the diabetic state. Upon treatment with 
insulin, the rate of synthesis is increased toward the rate found in 
the normal animal. The rate of synthesis of hexokinase II in the 
insulin-treated rat skeletal muscle is approximately 2,8 times that 
rate in the diabetic muscle. 
In the case of total cytosolic proteins, it can be seen that 
there is a difference between the diabetic when compared with the 
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Table IX. Preliminary synthesis studies of hexokinase 11^ 
Animal labeled leucine relative rate of 
3 3 
^tCi H /lOOg synthesis (% -x 10 ) 
Normal 26 6.34 
90 5.31 
Diabetic 25 3,04 
90 3.28 
^Each point represents the triplicate analysis of samples from 
two animals. 
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Table X. Synthesis of hexokinase II and cytosolic proteins 
Animal Time No. of 
animals 
Hexokinase II 
dpm/mg muscle 
a,b,c Cytosolic proteins^ 
-3 dpm X 10 /mg muscle 
Normal 0 
0.5 
1 
2 
3 
4 
3 
3 
4 
4 
4 
4 
2.11±0.45 
3.03±0.63 
4.95±0.66 
9.25±1.11 
16.4±1.49 
28.2±0.39 
40±6 
50±6 
108±41 
143±16 
255±41 
450±21 
Diabetic 0 
1 
2 
2.5 
3 
4 
4 
5 
4 
5 
6 
4 
1.0710.25 
2,88±0.72 
4.9510.76 
5.1510.58 
5.5610.21 
6.7410.91 
411 . 
91116 
122120 
152125 
186116 
223120 
Diabetic-
insulin 
0 
0.5 
1 
1.5 
2 
3 
4 
5 
4 
4 
0.3910.03 
1.8510.21 
4.6911.47 
5.8210.07 
10.811.39 
2.811.3 
3712 
84116 
105123 
18018 
^Time represents time of exposure to the label. 
^The numbers listed for times other then zero points have the 
zero point subtracted out. 
^Points represent the mean 1 standard deviation. 
Figure 9. Synthesis of hexokinase II (a) and total cytosolic proteins (b). Points are 
graphed as means ± standard deviation for normal (x,N), diabetic (A^d), and 
diabetic insulin-treated (#,DI) animals. For the total cytosolic proteins, 
3 
the dpm graphed represent dpm x 10 /mg muscle. Equations of the lines are; 
hexokinase II 
(normal) y = 5.24x - 0.91 
(diabetic) y = 1.85x + 0.05 
(insulin) y = S.lOx - 0.05 
cytosolic proteins 
(normal) y = 79xl0^x + 7.8x10^ 
(diabetic) y = 57xl0^x + 12x10^ 
(insulin) BSxlO^x - 4.4x10^ 
r = 0.99 
r = 0.98 
r = 0.98 
r = 0.98 
r = 0.98 
r = 0.98 
500 
400 
300 _ 
200 -
100_ 
time(hour) 
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normal or the insulin-treated rats. The rate of synthesis of the 
average of the total cytosolic proteins is approximately 1.^+ times 
greater in the normal as compared with the diabetic state. Again, 
treatment with insulin restored the synthesis rate to approximately 
normal values. 
If the rates of synthesis of hexokinase II are compared to 
the rates of synthesis of the average of the total cytosolic proteins, 
it appears that the change in the rate of synthesis of hexokinase II 
is specific, i.e., a change different from the average of the total 
cytosolic proteins. The rate of synthesis of hexokinase II is approx­
imately 2.8 times greater in the normal as compared to the diabetic 
state, while the rate of synthesis of the total cytosolic proteins is 
only approximately 1.4 times greater. It is clear that the change in 
hexokinase II synthesis is greater than that of the average of the 
cytosolic proteins. This is perhaps clearer if the data are represent­
ed in a different manner. From the counts incorporated into hexo­
kinase II and into total cytosolic protein, the relative rate of syn­
thesis was calculated: 
relative rate _ dpm incorporated into hexokinase II ^ ^ 
of synthesis dpm incorporated into cytosolic protein 
The relative rates of synthesis are shown in Table XI. The relative 
rate of synthesis of hexokinase IT is approximately 1.9 times higher 
in the normal as compared to the diabetic rat skeletal muscle. The 
relative rate of synthesis is approximately 1,7 times greater in the 
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Table XI. Relative rates of synthesis of hexokinase II in normal, 
diabetic, and diabetic insulin-treatêd rat skeletal muscle^ 
Animal Time No. of Relative rate 
(hr) animals of synthesis 
(% X 10 3) 
Normal 0.5 
1 
2 
3 
4 
3 
4 
4 
4 
4 
5.98+0.69 
5.6110.98 
6.48±0.39 
6.33+0.68 
6.47±0.71 
X = 6.1710.37 
Diabetic 1 
2 
2.5 
3 
4 
5 
4 
5 
6 
4 
3.1310.45 
3.9810.77 
3.6611.05 
2.9010.15 
2.96+0.15 
X = 3.2610.29 
Diabetic-insulin 0.5 
1 
1.5 
2 
4 
5 
4 
4 
5.0910.77 
5.6311.54 
5.7211.18 
6.0611.45 
X = 5.62+0.44 b,c 
^Numbers represent mean 1 standard deviation. 
< 0.0G5 versus diabetic. 
^Mo significant difference versus normal. 
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diabetic insulin-treated as compared to the diabetic rat skeletal 
muscle. Thus, upon treatment with insulin, the relative rate of syn­
thesis of hexokinase II in the diabetic rat skeletal muscle is restored 
to approximately that rate found in the normal rat skeletal muscle. 
The relative rate of synthesis of hexokinase II in the normal physio­
logical state is approximately equal to that in the diabetic insulin-
treated state. From these results, it is clear that the rate of syn­
thesis of hexokinase II is specifically decreased in the diabetic 
state and specifically increased upon treatment with insulin. 
Rate of degradation of hexokinase II and total cytosolic proteins 
Hexokinase II degradation was measured in normal, diabetic, and 
diabetic insulin-treated rats. These data are found in tabular form 
(Table XII) and in graphical form (Figure 10). The apparent rate 
constant of degradation, k^, can be calculated from the slope of the 
line as shown in equation (4). It is apparent from Figure 10 that the 
apparent rate constant of degradation of hexokinase II is increased in 
the diabetic state and decreased upon treatment with insulin. The 
apparent rate constant of degradation of hexokinase II in the normal 
— 1 —>1 
rat is 0.025 hour , in the diabetic rat 0.078 hour , and in the 
insulin-treated rat is 0.025 hour"^. These values, as well as the 
calculated half-lives (equation 4), are summarized in Table XIV. The 
rate constant of degradation of hexokinase II is 3 times greater in 
the diabetic state as compared to the normal state and to the diabetic 
insulin-treated state. 
Table XII. Degradation of liexokinase II in normal, diabetic, and diabetic insulin-treated rat 
skeletal muscle 
Animal Time No. of dpm dpm 
(hr) animals mg muscle mg muscle 14 C 
Normal 0 5 3.91+0.36 4.93±0.11 0.89+0.11 
12 4 3.41+1.21 2.85+0.33 1.19±0.03 
24 4 1.77+0.48 0.75+0.21 1.41+0.01 
36 5 2.83±0.73 1.06±0.44 2.25±0.52 
Diabetic 0 4 3.31+1.11 2.84+0.86 1.12+0.18 
12 4 2.66+0.28 1.24±0.71 2.14±0.62 
24 4 2.66±0.42 0.41±0.05 6.76±0.91 
36 4 3.51±1.11 0.16±0.06 18.57±0.11 
Diabetic-insulin 0 4 1.12+0.42 0.84+0.15 1.5I±0.29 
12 4 1.77±0.26 1.05+0.13 1.69+0.24 
24 5 1.64+0.16 0.65+0.01 2.55+0.03 
36 5 1.53+0.25 0.49+0.05 3.69+0.26 
^Points represent mean ± standard deviation. 
Figure 10. Degradation of hexokinase II in the skeletal muscle of the 
normal (x), diabetic (A), and diabetic insulin-treated 
( • ) rats. Points are graphed as the mean ±standard devia­
tion. Equations of the lines are; 
2 (normal) y = -O.Ollx + 0,011 r = 0.98 
(diabetic) y = -0.03Ux + 0,053 = 0,98 
2 (insulin) y = -O.Ollx + 0.034 r = 0,98 
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The average degradation of the total cytosolic proteins was also 
measured in the normal, diabetic, and diabetic insulin-treated state. 
These data are represented in Table XIII and Figure 11, Again, from 
the slopes the apparent rate constant of degradation, k^, can be 
calculated. The apparent rate constant of degradation of the average 
of the total cytosolic proteins is approximately 1.4 times greater in 
the diabetic as compared to the normal state and approximately 1.7 
times greater when compared to the diabetic insulin-treated state. 
These differences are clearly less than found for the'hexokinase II, 
indicating that the change in the apparent rate constant of degradation 
of hexokinase II is a specific change, i.e., a change which is differ­
ent from the average of the total cytosolic proteins. The apparent 
rate constants of degradation and apparent half-lives of the average 
of the total cytosolic proteins are summarized in Table XIV. 
To more clearly determine whether this change in the apparent 
rate constant of degradation of hexokinase II is specific, the 
3 14 . 
ratios found in hexokinase II were divided by H/ C ratios found in 
3 14 
the average of the total cytosolic proteins. These corrected H/ C 
ratios can then be graphed as in Figure 12. Again, the apparent rate 
constant of degradation, k^^ can be calculated from the slope. The 
apparent rates of degradation and the apparent half-lives from this 
are summarized in Table XV. From this it is clear that the apparent 
rate of degradation of hexokinase II is a specific change. The apparent 
half-life of hexokinase II is approximately 2.3 times greater in the 
normal as compared to the diabetic rat skeletal muscle. The apparent 
8 5 
half-life is approximately 2 times greater in the diabetic insulin-
treated rat as compared to the diabetic rat skeletal muscle. Fromm 
this it is clear that insulin, in some way, does affect the degrada­
tion of the hexokinase II. 
Table XIII. Degradation of the total cytosolic proteins in the skeletal muscle of the normal, 
diabetic, and diabetic insulin-treated rat 
Animal Time 
(hr) 
No. of 
animals 
dpm xld^ 
mg muscle 
14 -3 
C dpm xlO 
mg muscle 14c 
Normal 0 5 117±39^ 38±11 3.07+0.52 
12 4 70±18 22+3 3.39±1.31 
24 4 78+16 20±3 3.96±0.47 
36 6 147±22 27+3 4.54+1.52 
Diabetic 0 4 199124 69±8 2.7310.56 
12 4 309±61 99±34 3.4810.92 
24 4 115+16 30+5 4.2210.35 
36 4 175+48 37±19 4.76+0.25 
Diabetic-insulin 0 4 116±46 37±21 3.1811.08 
12 4 308±98 87 + 15 3.2710.44 
24 5 193±68 57±28 3.3610.98 
36 5 311±131 72±18 4.2611.32 
^The numbers listed for times other then zero time points have the zero point subtracted 
out. Points represent the mean ± standard deviation. 
Figure 11. Degradation of total cytosolic proteins in the skeletal 
muscle of the normal ( x ), diabetic ( A ), and diabetic 
insulin-treated ( • ) rat. Equations of the lines are: 
2 (normal) y = -O.OOSx + 0.005 r = 0.99 
(diabetic) y = -0.007x - 0.013 = 0.99 
2 (insulin) y = -0.004x + 0.018 r = 0.94 
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Table XIV. Degradation of hexokinase II and total cytosolic protein 
Animal hexokinase II cytosolic proteins 
k (hr~^)^ t, (hr)^ k (hr t, (hr)^ 
a '2 a ^ 
Normal 0,025^ 28° 0.012° 50° 
Diabetic 0.078 9 0.015 43 
Diabetic-insulin 0.025° 28 0.009 75° 
^k^ = apparent rate constant of degradation, 
^ti, = In 2/k,. 
-2 U 
°P < 0.005 versus diabetic. 
Figure 12. Degradation of hexokinase II relative to the average of the 
total cytosolic proteins in skeletal muscle of the normal 
( X ), diabetic ( A )^ and diabetic insulin-treated ( • ) 
rat. Equations of the lines are: 
2 (normal) y = -0.012x + 0.005 r = 0.95 
(diabetic) y = -0.028x + 0.070 r^ = 0.98 
(insulin) y = -O.OlUx - 0.022 r^ = 0.99 
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Table XV. Degradation of hexokinase II relative to the average of the 
total cytosolic proteins 
Animal k (hr ) t, 
d -1 
Normal 0.028±0.005* 25^ 
Diabetic 0.064±0.012 11 
Diabetic-insulin 0.032±0.008* 22^ 
^P<0.005 versus diabetic. 
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DISCUSSION 
The purpose of this study was to further characterize the cause(s) 
for the loss of measurable hexokinase II activity in the skeletal 
muscle of the diabetic rat. The results obtained in this study sug­
gest, as do those of other investigators (17,57), that there is a 
decrease in hexokinase II activity in the skeletal muscle of the strep-
tozotocin-diabetic rat and that, upon treatment with insulin, these 
levels are restored toward normal levels. 
The hormonal regulation of enzyme activity via covalent modi­
fication of pre-existing enzyme has been shown for several enzymes 
(see reference 112 for review). This covalent modification leads to 
differences in the specific activity of a particular enzyme under 
differing hormonal status. Thus, one would expect to see a difference 
in the specific activity in the presence of hormone as compared with 
the absence of hormone. The knowledge that effects of epinephrine 
are mediated through changes in phosphorylation states (113,114,174) 
makes this an enticing possibility for insulin (counteracting hor­
mone) also. One example of this mediation is seen with glycogen 
synthase. While skeletal muscle glycogen synthase is dephosphorylated 
in response to insulin, the enzyme is phosphorylated in response to 
epinephrine (118), and these changes are accompanied by changes in the 
activity of the enzyme. Therefore, a change in specific activity by a 
change in the phosphorylation state is not unprecedented with insulin. 
In addition to glycogen synthase (118), the phosphorylation state of 
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pyruvate dehydrogenase (115), and pyruvate kinase (121) have been re­
ported to change concomitantly with the specific activity in response 
to insulin. 
To determine the specific activity of an enzyme, one must be 
able to assay, not only the activity of the enzyme, but also the amount 
of protein exclusively of that enzyme. To date, a reliable determina­
tion of the specific activity of hexokinase II has not been accom­
plished. Specific activity determinations in the past have not used 
hexokinase II protein alone, but ratlier total extractab]e protein in 
the specific activity calculations (133,136). In addition, the deter­
minations of hexokinase II activity have not been entirely satisfactory. 
Gudnason et al. (13'0 reported that the tetrazolium dye staining tech­
nique used to detect hexokinase activity after electrophoresis is 
relatively insensitive. This insensitivity leads then to inconsistent 
determinations of hexokinase II activity using this method. Other 
investigators have determined hexokinase II activity in extracts by 
the evaluation of peak activity following ion-exchange chromatography 
(57), by heat inactivation of the hexokinase II (58), and by spectro-
photometric assays at differing glucose concentrations (47,50,58). 
None of these directly measures hexokinase II activity. Activity 
could be easily lost or some of the hexokinase II inactivated during 
the ion-exchange chromatography. In addition, the measurement of 
activity after heat inactivation is based on the assumption that all 
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of the hexokinase II is inactivated and no hexokinase I will be in­
activated. Bernstein and Kipnis (58) demonstrated that hexokinase I 
activity was lost during the heat inactivation step. 
An ELISA procedure was developed to determine the amount of 
hexokinase II protein in the muscle extracts. The ELISA method was 
shown to be specific for one protein, hexokinase II, with the Ouch-
terlony, the western blot assay, the linearity of the absorbance 
versus dilution of the extracts, and the hexokinase II recovery exper­
iments. This determination of hexokinase II protein, along with the 
activity determination utilizing iminunoprecipitation, allows us then 
to determine the specific activity of hexokinase II under different 
hormonal conditions. 
Katzen et al. (57) reported an approximate 40% minimum decrease 
in hexokinase II activity in the diabetic skeletal muscle utilizing 
starch gel electrophoresis and ion-exchange chromatography. The 
results of the study reported here show an approximate 55% decrease in 
hexokinase II activity in the diabetic skeletal muscle as compared 
to the normal, and approximately 49% less hexokinase II in the diabetic 
as compared to the diabetic insulin-treated rat skeletal muscle. The 
difference in the results presented here and Katzen's results could 
be due to the assays utilized as well as animal diet or animal treat­
ment protocols. However, Katzen did set his results as a minimum and 
in this respect the results presented do agree. The agreement 
in the percentage of hexokinase I activity in the skeletal muscle is 
much closer. In this study, 13% of the total activity in the skeletal 
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muscle extracts of normal rats was hexokinase I, with 17% hexokinase I 
in the diabetic insulin-treated animals. Katzen et al. (57) reported 
an approximate 15% of the total hexokinase activity in normal rat 
skeletal muscle as hexokinase I. 
The results of this study indicate that the specific activity 
of hexokinase II remains the same in the skeletal muscle of the normal, 
diabetic, and diabetic insulin-treated animal. This rules out covalent 
modification as a means of directly controlling the activity of pre­
existing enzyme. This does not exclude covalent modification as a 
signal for degradation of the protein say, by eliciting a conformation­
al change that would render the enzyme more susceptible to proteolysis. 
The lack of change in the specific activity does not rule out covalent 
modification of the enzyme that could lead to an increase in sensitivity 
to product inhibition or to other types of control. Thamby and Watkil 
(120) recently demonstrated that the dephosphorylation of acetyl-CoA 
carboxylase serves to increase the activity of the enzyme in the 
absence of citrate, an allosteric activator. So changes in the phos­
phorylation state can change the response of an enzyme to regulators 
and not directly change the activity. 
In the literature are found reports of proteins which are phos-
phorylated in response to insulin with no clear effect as yet as­
signed this phosphorylation, i.e., ATP-citrate lyase (151). Although 
researchers agree that ATP-citrate lyase is phosphorylated in response 
to insulin, some investigators have found no change in the enzyme 
activity upon phosphorylation (175), while others report an activa-
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tion upon phosphorylation in response to insulin (176). So, the com­
plete role that phosphorylation plays in the mediation of insulin's 
effects is not understood. What is clear is that results showing no 
change in the specific activity of an enzyme in response to insulin do 
not rule out a change in the phosphorylation state of that enzyme in 
response to insulin. 
Jarett et al. (177) has shown that their insulin mediators 
from skeletal muscle do not appear to mediate the changes in the early 
steps of glucose oxidation. These mediators appear to function by 
affecting the phosphorylation state and concomitantly the activity of 
the enzymes. Jarett's mediator did not stimulate glucose oxidation 
under the same conditions that it did mediate the stimulation of 
pyruvate dehydrogenase and glycogen synthase activity by changes in the 
phosphorylation state. These results suggest then that the action of 
insulin on the enzymes early in the glucose oxidation pathway, such as 
hexokinase II, may be mediated by a different mechanism than phos­
phorylation as a means to change the specific activity of the enzymes. 
A change in the specific activity of an enzyme or in an enzymes' 
repsonse to regulators could also be due to an interaction with 
activators or inhibitors and not to a covalent modification. These 
activator and inhibitor molecules could be responsive to insulin. If 
these molecules were not tightly bound, the effector molecule could 
disassociate from the enzyme during experimentation. 
Earlier studies by Katzen et al. (57) and others (15,52) using 
gel electrophoresis did show a loss of hexokinase II activity in the 
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diabetic muscle as compared with the normal muscle. The electrophoresis 
procedure should have separated the enzyme from any product or other 
small effector molecules such as glucose 1,6-diphosphate (84). This 
is true also in studies utilizing separation on ion-exchange columns 
(57). Therefore, the loss of hexokinase II activity in the diabetic 
state cannot be accounted for purely on the basis of inhibition or 
activation of pre-existing hexokinase II by product or other effector 
molecules not involving covalent modification of the protein. The 
observation that the specific activity of the hexokinase II was not 
altered by insulin does not rule out some fine and immediate control 
of hexokinase II activity by product or the proposed inhibitor, 
glucose 1,6-diphosphate (84). If inhibition by glucose 1,6-diphosphate 
or glucose 6-phosphate is a mechanism by which insulin controls 
hexokinase II activity, as suggested by Beitner (84), it certainly does 
not represent the only mechanism by which insulin regulates hexokinase 
II. This is also true concerning other possible effector molecules. 
The ELISA protocol did show that there are differences in the 
concentration of hexokinase II protein in the normal and diabetic 
states. There is approximately 2.4 times more hexokinase II protein 
in the normal rat skeletal muscle as compared with the diabetic rat 
skeletal muscle, and the amount of enzyme protein increases in the 
direction of normal upon treatment of the diabetic animal with insulin. 
So, it is clear from these studies that insulin is affecting the amount 
of hexokinase II protein. The amount of protein could be altered by 
a change in the rate of synthesis of the protein, the rate of dégrada-
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tion of the protein, or both. 
The relative rate of synthesis of hexokinase II was found to be 
approximately 1.9 times greater in the skeletal muscle of the normal 
animal as compared with the skeletal muscle of the diabetic animal. 
The relative rate of synthesis is increased upon treatment of the 
diabetic animal with insulin to approximately 1.7 times more than that 
rate in the diabetic animal. It is apparent from these studies that 
the rate of synthesis of hexokinase II does increase in response to 
insulin and that this increase may be specific. That is, the increase 
in hexokinase II synthesis is greater than that of the average of 
the total cytosolic proteins as shown by the relative rates of syn­
thesis. Using the concept of relative rates of synthesis not only 
allows us to determine that hexokinase II synthesis is stimulated 
preferentially, as compared with the average of the total cytosolic 
proteins, but also allows for (corrects for) any unequal precursor 
pool or variability in label injected. Thus, it appears that insulin 
affects the synthesis of hexokinase II in some manner. 
It is also important to show that hexokinase II synthesis does 
decrease relative to the average of the total cytosolic proteins 
because it has been shown that overall protein synthesis is decreased 
in the diabetic rat skeletal muscle (89,95,178). A decrease in 
hexokinase II synthesis would be expected based on these results. 
Investigators (92,93) have reported that there is a decrease in 
peptide-chain initiation and an overall decrease in total RNA (89, 
95) in diabetic muscle. Kelly and Jefferson (179) have recently 
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shown that the site of insulin action on overall protein synthesis in 
skeletal muscle lies in the formation of the 40s initiation complex. 
The data on the synthesis of the average of the total cytosolic 
proteins obtained in this study are in good agreement with the data from 
other groups. Using a constant intravenous infusion method and the 
specific activity of tyrosine, Flaim et al. (90) found a 22% fall 
in overall protein synthesis in the diabetic muscle as compared to the 
normal muscle. In the study presented here an approximate 27% fall 
in protein synthesis was seen comparing the diabetic to the normal 
state. An approximate 32% lower rate of protein synthesis was seen 
in the diabetic rat skeletal muscle as compared to the rate in the dia­
betic insulin treated rat skeletal muscle. This is in good agreement 
with the results of Pain et al. (94) who reported a 35% decrease in 
protein synthesis in the diabetic as compared to the diabetic insulin-
treated rat skeletal muscle. 
A number of reports have demonstrated an accumulation of mRNA in 
response to insulin, i.e., reports of the accumulation of the correspond-
in mRJiAs' of albumin (180), amylase (181), tyrosine aminotransferase 
(98), pyruvate kinase (99), glucokinase (9.10), and fatty acid 
synthetase (182). In addition, Chomczynski et al. (183) demonstrated 
that in rat mammary gland, insulin did not stabilize the transcript 
but rather insulin was essential for the synthesis of the 25,000 MW 
casein mRNA in the presence of glucocorticoids and prolactin. In 
addition to evidence of insulin regulation at the transcriptional 
level, there is evidence that the regulation of 3-hydroxy-3-methyl 
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glutaryl-CoA reductase by insulin in human mononuclear leucocytes is 
at a post-transcriptional level (184). Insulin has also been shown to 
affect the phosphorylation of at least one protein involved in the 
translational initiation complex (119) and perhaps another (179). 
This could be important to the regulation of protein synthesis by 
insulin. Regulation by changes in the rate of translational initia­
tion represents a rapid, short-term mechanism whereby a cell could 
modify gene expression. In other tissues, it is clear that insulin 
does specifically increase the synthesis of particular proteins over 
other proteins. However, little work has been done on specific pro­
teins in skeletal muscle in this context. Whatever the mechanism of 
control of hexokinase II synthesis by insulin is, it is important to 
establish that the rate of synthesis of a particular protein does in­
deed change before undertaking more detailed studies into the exact 
nature (cause) of this change. It is clear from these studies that 
insulin does specifically increase the synthesis of hexokinase II. 
Although there is a change in the relative rate of synthesis of 
hexokinase II in the diabetic state, this does not preclude a change 
in the rate of degradation of hexokinase II as well. Numerous inves­
tigators have demonstrated an increase in overall protein degradation 
in the skeletal muscle of the diabetic rat (95,148,185). This study 
is in agreement with those reports. Millward et al. (185) reported 
a 29% increase in the rate of degradation of the average of the 
protein in diabetic rat skeletal muscle as compared to the degra­
dation in the normal rat skeletal muscle. These studies utilized the 
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constant infusion method employing[^^cjtyrosine and calculation of the 
rate of degradation from the measured rates of synthesis. This value 
is in good agreement with that found by Pain et al. (94) of a 27% in­
crease in the average rate of protein degradation upon the induction 
of the diabetic state. They also reported a 20% increase in the rate 
of protein degradation in the diabetic as compared to the diabetic 
insulin-treated animal. These studies of Pain et al. (94) involved 
the calculation of the rate of degradation from the measured rates of 
synthesis obtained after a single dose of labeled amino acid. 
The results of the study presented here agree with both these 
investigations in that a 28% increase in the apparent rate constant 
of degradation was obtained for the average of the total cytosolic 
proteins in the diabetic skeletal muscle as compared to the normal 
animal. So the results from the three studies, each employing a 
different method, correlate fairly well. In the study presented here 
a 43% increase in the apparent rate constant of degradation was seen, 
in the diabetic animals as compared to the diabetic insulin-treated 
animal as well. 
The apparent half-life of hexokinase II was found to be approx­
imately 3 times greater in the normal and diabetic insulin-treated 
rat skeletal muscle as compared to the half-life in the diabetic 
skeletal muscle. As in the synthesis studies, it is important to 
compare this to the total cytosolic proteins also. The incorporation 
of label into hexokinase II must be compared with that label incor­
porated into the average of the total cytosolic proteins to take into 
103 
account reutilization and to determine the specificity of change. 
Increased reutilization would tend to reduce the rate of decay of the 
radioactive label in the protein and so increase the apparent half-
life. Since the goal is to compare the apparent half-lives in the 
normal, diabetic, and diabetic insulin-treated animals, this must be 
taken into account. This was done and these data are shown in Table 
XV and Figure 12. The half-life calculated from the incorporation 
into hexokinase II relative to the cytosolic proteins is approximately 
2.3 times greater in the normal as compared to the diabetic state, and 
approximately 2 times greater in the diabetic insulin-treated state 
as compared to the diabetic state. A greater difference is seen 
between the normal and diabetic states when the total cytosolic proteins 
are considered. Comparison of the corrected half-lives indicates that 
the degradation of hexokinase II is increased specifically, i.e., a 
change greater than that of the average of the total cytosolic proteins. 
This study cannot answer the question of whether this increase 
in degradation is the result of a specific signal dealing with the 
hexokinase II or the result of the instability of the enzyme (17,10) 
coupled with an increase in the proteolytic environment in the diabetic 
state (108,185). Many investigators have demonstrated that hexokinase 
II is stabilized in vitro by the addition of glucose (.17 49,58,111). 
Rose and Warms (111) demonstrated that K"*" also stabilizes hexokinase 
II and that this effect of is additive with the stabilization effect 
of glucose. Therefore, the increase in the apparent rate constant of 
degradation of hexokinase II in the diabetic state could be due to a 
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decreased stability of the enzyme as a result of a lowered K^' and 
glucose concentrations in the cell. This increased instability is 
coupled with an increase in proteolytic pathways and so the degradation 
of hexokinase II increases. 
Rose and Warms also reported that glucose was not necessary for 
the stabilization of hexokinase II in ascities cells. They suggest 
that a thioredoxin system on the ascities cell maintains the enzyme 
in the reduced state, which has greater stability, and that hexokinase 
II which is oxidized is rapidly degraded. The oxidized form of hexo­
kinase II could not be detected in cells in which both glucose and k"*" 
had been removed, so it appears that this oxidized form must be rapidly 
degraded. Rose and Warms speculated that the oxidation of the hexo­
kinase II may serve to change the conformation of the protein and in 
doing so expose a site for a protease. Fagen and Goldberg (186) have 
reported that overall protein degradation in isolated skeletal muscle 
does not correlate with the overall reduction-oxidation status of the 
muscle. However, this does not rule out the control of the degrada­
tion of specific enzymes by a decrease in stability due to changes in 
their reduction-oxidation status. 
At any rate, the results from this study do suggest that there 
is some mechanism by which hexokinase II is rendered less stable in 
the diabetic state, i.e., more susceptible to proteolysis. Whether 
this is due to the loss of stabilization factors or to some signal for 
increased degradation of hexokinase II, such as phosphorylation or, 
as suggested by Rose and Warms (ill), oxidation of the hexokinase II 
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protein, is not known at the present time. 
Under steady state conditions equation (2) is true. If the per­
cent change between the relative rate of synthesis of hexokinase II in 
the normal as compared to the diabetic rat, as well as this difference 
between the relative rate constants of degradation are used in equation 
(2), then the percent difference in the hexokinase II activity can be 
calculated. From this the calculated difference in the hexokinase II 
activity in the normal and diabetic muscle is 40% while the experi­
mental difference is 56%. This same calculation can be made comparing 
the diabetic insulin-treated and diabetic rat. The calculated differ­
ence in the hexokinase II activity is UG%, while the experimental 
values give a difference of 46%. These experimental values are in good 
agreement with the calculated values. This same level of agreement 
has been obtained by others in studies on the turnover of glucokinase 
(101). 
To summarize, this study indicates that the decrease in the 
measurable hexokinase II activity in the skeletal muscle of the strep-
tozotocin-diabetic rat is due, in part, to a decrease in the synthesis 
and an increase in the degradation of the protein. This study also 
indicates that this loss in activity may not be due to covalent modi­
fication as a mechanism for directly affecting the enzyme activity. 
The return of the level of hexokinase II activity, as well as the 
synthesis and degradation rates to near normal upon treatment of the 
diabetic animal with insulin, indicates that insulin does affect these 
phenomena. 
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